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During the last twenty years the prevalence of diabetes has increased 
dramatically in the world, and the disease is now one of the largest global health 
emergencies of the 21st Century1. 
Previous studies estimated that the number of diabetic patients worldwide 
would reach 366 million in 20302; however, that number is already exceeded. At 
the end of 2015 there were 415 million people with diabetes in the world, and 
there will be 642 million people with diabetes in 20403 (Figure 1). In addition to 
the 415 million adults with diabetes, there are 318 million adults with impaired 
glucose tolerance, which puts them at high risk of developing the disease in the 
future3. 
 
Figure 1: Prevalence of diabetes in 2015 and future estimation in 2040 worldwide1. 
The last study of diabetes mellitus in Spain shows that the prevalence of this 
disease in adults was 13.8% in 2011; in addition, almost half of them did not know 
they had the disease (6.0%)4. 
2 INTRODUCTION 
2.1 The pandemic of diabetes mellitus 
 24 
 
In 2012 around 1.5 million deaths were directly caused by diabetes and 
another 2.2 million deaths were attributable to high blood glucose5,6. 
Furthermore, direct medical cost of diabetic patients was 8% of total public health 
expenditures in Spain7 and 12% of global health expenditure in the world3. The 
increasing social cost and the increasing prevalence of diabetes mellitus, 
combined with the high mortality and morbidity related to it, suggest the 
importance of developing effective ways to treat and manage diabetes. 
Diabetes mellitus is a group of metabolic diseases characterized by chronic 
hyperglycemia due to insufficient insulin production or due to impaired 
responsiveness to insulin produced by the pancreas8. Currently, according to the 
World Health Organization (WHO), the following criteria are utilized for the 
diagnosis of diabetes mellitus9,10 (Table 1): 
 
Table 1: WHO diabetes diagnosis criteria8. 
There are two main types of diabetes.  The first is type 1 diabetes mellitus 
(T1DM), which is characterized by insufficient insulin production as a result of 
pancreatic β-cells destruction via an autoimmune reaction. T1DM develops 
according to certain hereditary factors plus environmental or inducement 
factors11,12. T1DM is classified as fulminant, acute or slowly progressive 
depending on the manner of onset13. 
Type 2 diabetes mellitus (T2DM), which is the most common form of diabetes, 
is characterized by the development of insulin resistance in the peripheral tissues 
2.2 Diagnosis and main types of diabetes mellitus 
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and by the failure of pancreatic β-cells to produce sufficient insulin due to the 
long-term need to increase insulin secretion to compensate for insulin 
resistance14. T2DM is associated with multiple genetic factors15,16 and unhealthy 
lifestyle habits, such as daily high fat diet and lack of exercise, which finally ends 
in overweight and obesity. Onset of T2DM commonly occurs in middle age or 
later, despite the fact that T2DM has currently been shown to be increasing in 
young people and children. This type of diabetes accounts for over 90% of all 
diabetes cases around the world17. 
Obesity is defined as a body mass index (BMI) of ≥ 30 kg/m2 (Table 2). 
 
Table 2: WHO classification of adult obesity according to BMI18. 
The prevalence of has risen since 1960 and has increased to 54.9% of adults 
in the last decade19. In 2014, 38% of adult men and 40% of adult women aged 
18 years and older were overweight20 (Figure 2 and 3). 
2.3 Obesity and T2DM 
2.3.1 Obesity 
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Figure 2: Age-standardized prevalence of obesity in men aged 18 years old and over (BMI ≥ 30 kg/m2), 
201421. 
 
Figure 3: Age-standardized prevalence of obesity in women aged 18 years old and over (BMI ≥ 30 
kg/m2), 201421. 
Obesity has become a serious global health problem, overall, in developing 
and industrialized countries. Moreover, obesity is responsible for enormous 
health care costs due to health risks associated with this disease, e.g.: 
cardiovascular disease, cancer and diabetes mellitus. For these reasons there is 
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a need to understand the mechanisms and pathogenesis of obesity-related 
diseases for developing new treatments and prevention strategies22. 
The prevalence of T2DM is rising in parallel with obesity; in fact, more than 
90% of individuals with T2DM are obese23. Primarily, the relationship between 
obesity and T2DM is based on impaired lipid and carbohydrate metabolism 
regulated by insulin24, which causes insulin resistance. Frequently, this insulin 
resistance is associated with obesity. 
In contrast, certain populations with a high prevalence of obesity show a low 
prevalence of T2DM. In this way, we can indicate that being obese is not an 
indispensable condition for developing T2DM; indeed, lean individuals can 
develop this devastating disease25,26.  
On the one hand, some studies indicate that the majority of obese people do 
not develop T2DM, and it only appears in people who are genetically predisposed 
to developing it27. On the other hand, many epidemiological studies suggest that 
obesity plays a direct role in the development of T2DM, scoring it as the major 
risk factor for this metabolic disease28,29 (Table 3). 
 
Table 3: Estimated increased risk of suffering disease for obese versus lean population30,31. 
2.3.2 Relationship between obesity and T2DM 
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Insulin is a peptide hormone produced and secreted by β-cells in the Islets of 
Langerhans in the pancreas, in response to high blood glucose levels32. In 
pancreatic β-cells, insulin is synthesized and processed by removing C-peptide, 
the center of the molecule, from the precursor molecule proinsulin through 
proteolytic enzymes33. 
The three main target tissues for insulin action are liver, muscle and adipose 
tissue34. Insulin maintains blood glucose levels from 4 to 7nM regardless of 
nutritional status, but under conditions of high blood glucose levels, insulin 
promotes glycogen and lipid storage and inhibits the breakdown of glycogen 
(glycogenolysis) and the de novo synthesis of glucose (gluconeogenesis) in the 
liver35. In addition, in muscle insulin stimulates glucose uptake for storage in the 
form of glycogen34 and inhibits protein degradation while increasing the release 
of amino acids36. Likewise, in adipose tissue, insulin inhibits lipolysis, reducing 
the release of free fatty acids and glycerol into bloodstream, while also triggering 
glucose uptake and lipid storage34,37. 
Insulin produces other effects besides nutrient metabolism on non-target 
tissues.  For example, in the brain, insulin is responsible for appetite 
suppression38–40, which has been shown to be reduced in insulin resistant and 
obese people41. Insulin also has an effect on vascular cells, where it stimulates 
vasodilatation and capillary recruitment enhancing glucose delivery and glucose 
uptake by the muscle38,42. 
The main effects of insulin action on different tissues are summarized in Table 
4. 
2.4 Insulin resistance in obesity and T2DM 
2.4.1 Insulin: the regulator of metabolism 
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Table 4: Direct and indirect effects of insulin on metabolic processes. Modified from Newsholme and 
Dimitriadis43. 
Insulin signaling regulates glucose, lipid and energy homeostasis, 
predominantly via its action on liver, skeletal muscle and adipose tissue44. 
Once secreted by β-cells, insulin binds to the insulin receptor (IR). The IR is 
formed by two extracellular α subunits and two transmembrane β subunits which 
are linked by disulfide bonds45. On the β subunits there is a tyrosine kinase 
domain, which is activated by autophosphorylation when insulin binds to the IR46. 
Downstream, the IR activation induces the recruitment of insulin receptor 
substrates (IRSs), via phosphorylation of certain tyrosine residues by the kinase 
activity of activated IR. Several intracellular IRSs have been identified47; however, 
IRS-1 and IRS-2 are the most important. IRS-1 is the main IRS responsible for 
controlling insulin action in muscle, while IRS-2 is essential for insulin signaling 
in the liver48. Phosphorylated IRS proteins are responsible for mediating 
activation of the two major insulin-signaling pathways: the mitogen activated 
2.4.2 Insulin signaling 
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protein kinase (MAPK) pathway, which is important for cellular growth and 
development; and the phosphatidylinositol 3-kinase (PI3K)-protein kinase B 
(AKT) pathway, which is crucial for metabolic functions, mainly glucose and fat 
metabolism47,49. 
PI3K is formed by a regulatory p85 subunit50, which has two proto-oncogene 
tyrosine-protein kinase (Src) homology 2 (SH2) domains that interact with 
phosphotyrosine residues on IRSs, and a catalytic p110 subunit51, which is able 
to phosphorylate phosphatidylinositol-4,5-biphosphate (PIP2), a plasma-
membrane glycolipid, to phosphatidylinositol-3,4,5-trisphosphate (PIP3)52. PIP3 
recruits AKT, one of the main metabolic steps of insulin signaling, and 3-
phophoinositide-dependent kinase-1 (PDK1) to the plasma membrane via its 
pleckstrin homology (PH) domain53. 
Once localized to the plasma membrane, AKT is phosphorylated at threonine 
308 (Thr308) by PDK154 and at serine 473 (Ser473) by the mammalian target of 
rapamycin complex-2 (mTORC2)55,56. Fully activated AKT is separated from 
plasma membrane to cytoplasm. 
There are two isoforms of AKT (AKT1 and AKT2). AKT1 is required for normal 
growth, is involved in cellular survival, protein synthesis and inhibition of 
apoptosis, but dispensable for the maintenance of glucose homeostasis57. In 
contrast, AKT2 is essential for the maintenance of normal glucose homeostasis58. 
AKT is capable of mediating changes in other kinases, such as glycogen 
synthase kinase 3 (GSK3), which is down-regulated by AKT phosphorylation59. 
This results in dephosphorylation and activation of glycogen synthase (GS) leads 
glycogen production47. In addition, AKT has other targets, such as AKT substrate 
of 160 kDa (AS160), involved in glucose transporter translocation; and the 
mammalian target of rapamycin complex-1 (mTORC1), a signaling hub involved 
in many cellular processes; sterol regulatory element binding protein-1c (SREBP-
1c), which mediates many of insulin’s effects on lipogenesis and cholesterol 
homeostasis60,61; and the forkhead box (FoxO) transcription factor, involved in 
gluconeogenesis processes62,63 (Figure 4). 
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Figure 4: Liver-specific insulin signaling for the regulation of hepatic lipid and glucose metabolism63. 
Obesity is one of the most important risk factors for developing insulin 
resistance64. The term insulin resistance was described and defined in 1988 by 
Reaven as “a state (of a cell, tissue, system or body) in which greater than normal 
amounts of insulin are required to elicit a quantitatively normal response” 65. 
In mechanistic terms, insulin resistance can occur at three different levels: 
- Before the binding of insulin with the IR, such as increased insulin 
degradation or insulin competing to bind other proteins besides IR. 
- At level of the IR, due to alterations in binding affinity or receptor levels. 
- Downstream of the IR interaction, due to any of a number of changes from 
the hormone-receptor complex to the final effects66. 
Patients with insulin resistance present with impaired glucose tolerance due to 
reduced ability of peripheral tissues to uptake and metabolize glucose67. 
However, the precise cause(s) of T2DM and the mechanisms which underlie 
this metabolic disease in target cells are still being elucidated. 
2.4.3 Insulin resistance 
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Formerly, adipose tissue was thought to be inactive in terms of metabolic 
functions; however, recently its role in metabolism has been described68 and it 
has been defined as “a highly active closely-regulated metabolic tissue” 69. 
There are two principal theories seeking to explain the origin of insulin 
resistance. The fat overload theory70,71 proposes that insulin resistance is 
triggered by elevated levels of free fatty acids (FFAs) in blood72, which can vary 
considerably with dietary intake. When there is high fat intake, adipose tissue 
begins to store large quantities of triglycerides, in order to prevent high blood 
triglyceride levels. However, when fat intake remains higher than fatty acid 
oxidation ratio, triglycerides begin to accumulate in liver, skeletal muscle and 
pancreatic β-cells, resulting in insulin resistance and impaired insulin secretion73–
76. In addition, intermediates from incomplete β-oxidation as diacylglycerol (DAG) 
and ceramide accumulated in these cells, which inhibits the insulin-signaling 
pathway77. 
An alternative theory to explain the development of insulin resistance is 
inflammation theory. It is known that obesity itself induces an inflammatory state 
in which macrophages are believed to infiltrate adipocytes, thus producing an 
augmented inflammatory response78,79. Consequently, different pro-inflammatory 
cytokines, such as tumor necrosis factor-alpha (TNF-α)80–82, interleukin-6 (IL-6)83, 
interleukin-1β (IL-1β) and monocyte chemoattractant protein-1 (MCP-1)84, are 
secreted from adipocytes. Increased secretion of these cytokines impairs insulin 
signaling and glucose transport in peripheral tissues85 (Figure 5). 
In addition, both theories can be combined in one due to fat overload, through 
production of metabolites such as DAGs and ceramides, causes the activation of 
inflammatory pathways inducing an insulin resistance state. 
 33 
 
 
Figure 5: The two general theories to explain insulin resistance; fat overload theory (white background 
on the left) and inflammation theory (grey background on the right)86. 
The liver is one of the three principal target tissues for insulin action. The liver 
regulates systemic insulin levels through hepatic insulin clearance and maintains 
normoglycemia during fasting conditions87.  
Under insulin-resistant conditions, hepatic gluconeogenesis and 
glycogenolysis are inadequately suppressed, resulting in hyperglycemia under 
both fasting and non-fasting conditions88. Also, a common response to insulin 
resistance is increased secretion of insulin by the pancreas; the resulting 
hyperinsulinemia induces an overstimulation of lipogenesis. Dyslipidemia is 
another common consequence of insulin resistance, being characterized by 
hypertriglyceridemia together with low high-density lipoprotein (HDL) cholesterol 
and elevated low-density lipoprotein (LDL) cholesterol in circulation. This profile 
is often present in individuals with T2DM89. 
In addition, insulin resistance developed by skeletal muscle and adipose tissue 
affects glucose disposal and lipolysis due to the inability to take up glucose in 
response to insulin. Furthermore, insulin resistance established in adipose tissue 
2.4.4 Insulin resistance in liver, skeletal muscle and adipose tissue 
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leads to unregulated lipolysis, which causes high blood free fatty acids levels and 
contributes to increased hepatic glucose output68,90 (Figure 6). 
 
Figure 6: Liver, skeletal muscle and adipose tissue insulin resistance68. 
Many organs and cells use glucose as their major energy source, because 
numerous basic maintenance functions depend on glucose supply. In fact, the 
liver is the organ responsible for regulating glucose homeostasis by controlling 
the balance between glucose output during fasting periods, or glucose uptake 
during feeding periods91,92. 
During feeding periods, insulin mediates hepatic glucose uptake which can be 
stored as glycogen (glycogenesis) or can be oxidized to supply necessary energy 
(glycolysis)93. 
However, during fasting periods, other hormones such as glucagon stimulate 
glucose production by glycogen degradation (glycogenolysis) or activates de 
novo synthesis of glucose using glycerol, lactate and certain amino acids 
(gluconeogenesis)94.  
2.5 Hepatic glucose metabolism 
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In the fed state, glucose is transported in circulation from the gut and it is 
metabolized by a process regulated mostly by insulin. Insulin stimulates the liver 
and muscle to store excess glucose as glycogen via the process of 
glycogenesis59,95. 
Circulating insulin, secreted by the pancreas in response to feeding, is cleared 
primarily by the liver, and to a lesser extent by the kidney96. Once insulin binds to 
IR in the liver, IR autophosphorylation occurs, inducing a signaling cascade via 
PI3K with the subsequent phosphorylation and activation of AKT91,97. The insulin-
IR complex is then endocytosed and insulin is dissociated from the IR. Most 
evidence suggests that insulin is degraded at this point96,98. 
Phosphorylated and activated AKT leads to fatty acid synthesis, activation of 
protein synthesis pathways and changes in other kinases, as GSK3, which is 
down-regulated by AKT phosphorylation59. This results in dephosphorylation and 
activation of GS leading to glycogen production47 from glucose, which enters to 
the hepatocyte through glucose transporter 2 (GLUT2) located at the cell surface. 
In addition, forkhead box O1 (FoxO1) transcription factor is phosphorylated by 
full activated AKT, precluding its translocation from the cytoplasm to the 
nucleus95,97,99,100 (Figure 4). 
During glycogenesis, glucose enters in the liver through GLUT2101,102, which 
mediates the equilibrium of glucose concentrations in blood and 
hepatocytes101,103,104 but is not directly regulated by insulin103. GLUT2 is the major 
glucose transporter in hepatocytes, but is also expressed in pancreatic islets, 
brain, intestine and kidney105,106. 
Glycogenesis involves three different phases. In the first phase, glucose is 
metabolized to glucose-6-phosphate (G6P) by the action of glucokinase 
(GCK)107,108; this enzyme is expressed by hepatocytes and pancreatic β-cells and 
is involved in both glycogenesis and glycolysis. In the second phase, G6P is 
converted to glucose-1-phosphate (G1P); and, in the third phase, G1P reacts 
2.5.1 The liver in the fed state 
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with uridine triphosphate (UTP) forming uridine diphosphate-glucose (UDP-
glucose) from which glycogen is finally obtained by the action of GS. 
In addition, insulin secreted by the pancreas in response to feeding activates 
another metabolic pathway named glycolysis. Glycolysis occurs in the liver and 
is characterized by the conversion of glucose into pyruvate. As occurs in 
glycogenesis, glucose first enters in the hepatocyte through GLUT2101,102 and is 
phosphorylated to G6P by the action of GCK. After that, however, G6P is 
processed through a different pathway that yields pyruvate as a final product109. 
Pyruvate can be converted into lactate or acetyl CoA which directly enters the 
Krebs cycle to generate energy in form of adenosine triphosphate (ATP)100,110 
(Figure 7). 
GCK, which is involved at the beginning of both glycogenesis and glycolysis, 
is regulated mainly by insulin; however, its transcription in the liver is controlled 
by several transcription factors as FoxO1111,112, SREBP-1c113, hepatocyte 
nuclear factor-4 (HNF-4)111,112, peroxisome proliferator activated receptor gamma 
(PPARγ)113, hypoxia-inducible factor-1 (HIF-1)114,115, liver X receptor (LXR)113, 
transcription factor E3 (TCFE3)116 and Kruppel-lie factor-6 (KLF-6)117. 
 
Figure 7: Simplified scheme of the major biochemical pathways activated during postprandial hepatic 
glucose uptake and storage118. 
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In the fasted state, in response to decreasing blood glucose concentrations, 
circulating insulin levels and hepatic insulin signaling decrease; as a 
consequence, dephosphorylated and active GSK3 phosphorylates and 
inactivates GS, inhibiting glycogen synthesis by the liver119. In addition, the 
pancreas initiates glucagon secretion, a peptide hormone which has receptors in 
the brain, adipose tissue, heart, liver and kidney120. 
In this metabolic condition, the energy of the entire body depends on glucose 
produced by the liver and, to a lesser extent, by the kidney,  the two organs 
capable of carrying out glucose production and secretion121. In fact, glucose from 
glycogen storage in the muscle is only used to maintain its contraction abilities122–
124. 
Glucose release by the liver is essential to maintain energy supply to the 
muscle during physical exercise122,123, but overall it is indispensable to maintain 
energy supply to essential organs for life as the brain, which depends on a 
continuous flow of glucose by the blood to maintain its basic functions124,125. 
Glycogenolysis begins when glucagon binds to its receptor named G-protein-
coupled glucagon receptor (GCGR)126, which is present at the cell surface of 
hepatocytes. When glucagon interacts with GCGR, a downstream signaling 
cascade is initiated: intracellular cyclic adenosine monophosphate (cAMP) levels 
increase via adenylate cyclase, leading to the activation of protein kinase A 
(PKA), which activates glycogen phosphorylase119. Glycogen phosphorylase, the 
main enzyme involved in glycogenolysis process, is active when it is 
phosphorylated at serine 14 and is capable of removing a glucose residue from 
the non-reducing end of a glycogen chain, generating G1P127. Subsequently, 
G1P is converted to G6P by the action of a debranching enzyme and, finally, G6P 
is converted into glucose by glucose-6-phosphatase (G6Pase)128,129. Glucose is 
then released from the hepatocytes into the bloodstream. 
2.5.2 The liver in the fasted state 
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Figure 8: Glucagon hepatic signaling pathway128. 
Glucagon signaling also induces hepatic glucose production from other 
substrates, such as glycerol, lactate, alanine and pyruvate, in a process named 
gluconeogenesis (Figure 8). 
Gluconeogenesis is the reverse process of glycolysis—the generation of 
glucose from pyruvate—and it occurs when fasting exceeds ~8 hours in humans; 
at this time, gluconeogenesis replaces the breakdown of glycogen130. 
Molecularly, glucagon signaling inhibits pyruvate dehydrogenase (PDH), 
impeding glycolysis and also blocking the conversion of pyruvate to acetyl CoA. 
This mechanism allows pyruvate to be used as a substrate in 
gluconeogenesis120. 
Other gluconeogenesis precursors are amino acids such as alanine and 
glutamine, which are converted into intermediates of the tricarboxylic acid cycle; 
lactate, which is converted into pyruvate by lactate dehydrogenase (LDH); and 
glycerol, which derives from increased lipolysis within white adipose tissue (WAT) 
under fasting conditions, where it is transformed into dihydroxyacetone 
phosphate (DHAP), a gluconegenic intermediate, by glycerol kinase (GK) 
action119. Each of these precursors enters the gluconeogenic pathway through 
pyruvate, excepting glycerol which enters in this pathway as DHAP. All of them 
will be transformed into G6P131,132.  
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Gluconeogenesis happens primarily by three different steps133. The first step 
is characterized by the action of pyruvate carboxylase (PC), activated by 
mitochondrial acetyl-CoA (produced from increased fatty acid oxidation under 
fasting conditions), which transforms the pyruvate into oxalacetate119. 
Oxalacetate is converted into phosphoenolpyruvate (PEP) by 
phosphoenolpyruvate carboxykinase (PEPCK)134,135. Classically, PEPCK is 
considered the principal enzyme mediating gluconeogenesis99. In the second 
step, PEP is transformed into fructose-1,6-biphosphate (F1,6BP) by six 
sequential reactions, which are the reverse of glycolysis reactions. At this point, 
F1,6BP is transformed first, to fructose-6-phosphate (F6P) by the action of 
fructose biphosphatase (FBPase), and secondly, to G6P by a reverse 
reaction131,136. Finally, in the third step, the dephosphorylation of G6P to glucose 
occurs by G6Pase action137,138 (Figure 9). G6Pase is expressed exclusively in 
liver and kidney, the only two organs capable of executing glucose 
production121,139–141. Glucose is then released from the hepatocytes into the 
bloodstream. 
 
Figure 9: Simplified scheme of the major biochemical pathways activated during post-absorptive hepatic 
glucose production118. 
In addition, cAMP response element-binding protein (CREB) and FoxO1, 
which is the best characterized and the most abundant FoxO family member in 
hepatocytes, represent the main transcriptional factors involved in hepatic 
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glucose production regulated by insulin/glucagon action142–145. Molecularly, in the 
fasted state, as consequence of active glucagon signaling146, nuclear CREB is 
activated via serine 133 phosphorylation by PKA, due to increased cAMP 
concentrations in the liver147; whereas FoxO1 remains in an un-phosphorylated 
state in the nucleus. Both activated CREB and un-phosphorylated FoxO1, 
increase the transcription rates of  Pepck95,100,143–145 and G6p145,148 promoting 
hepatic glucose production. However, in the fed state and via insulin signaling, 
serine 133 of nuclear CREB is not phosphorylated; whereas AKT activation 
induces FoxO1 phosphorylation. As consequence, FoxO1 is excluded from the 
nucleus, ubiquitinated and degraded142,149,150. As a consequence, hepatic 
glucose production decreases, whereas glycogenesis and glycolysis increase99. 
IDE is a 110-kDa metalloprotease, which requires a zinc atom to exert its 
catalytic activity (Figure 10), first identified and named based on its ability to bind 
to and degrade insulin96. IDE also degrades a number of other intermediate-sized 
(<80 amino acids) bioactive peptides, including glucagon, amylin and the amyloid 
β-protein (Aß)151. 
 
Figure 10: Crystal structure of a homodimer of IDE. IDE-N, IDE-C, catalytic zinc ion, and door subdomain 
are colored in cyan, green, grey and red, respectively; while the surface of catalytic chamber of IDE is in 
grey152. 
2.6 Insulin-degrading enzyme (IDE) 
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IDE is ubiquitously expressed at varying levels in both insulin-responsive and 
nonresponsive cell types.  Subcellularly, the protease is localized primarily within 
the cytosol, but it has been reported to exist within a number of intracellular 
vesicles, organelles, and associated with membranes, and it is also secreted into 
the extracellular space96,153,154. This distribution suggests a multifunctional role 
for this protein.  
The first IDE substrate described was insulin. Insulin has a short half-life in the 
bloodstream, due to the high efficiency of insulin clearance mechanisms, which 
occur primarily in liver and kidney, but also take place to a limited extent, in many 
other tissues96,155. Insulin clearance occurs by receptor-mediated internalization 
following the binding of insulin to the IR. Acidification of the endosomes after 
internalization leads to dissociation of insulin from its receptor. A subset of 
endosomes are returned to the cell surface, thus recycling the IR, while other 
endosomes travel to the lysosome, where insulin is believed to be degraded156–
158. By this way, almost 50% of internalized insulin is degraded. 
IDE also degrades and inactivates a number of other hormones, including 
glucagon, amylin159 and beta-amyloid peptide (Aβ)160. In addition, IDE degrades 
hormones, grow factors and neurotransmitters including endorphins, 
somatostatin, insulin-like growth factor II (IGF-II) and transforming growth factor 
alpha (TGF-α)96,151. 
The substrate recognition mechanism of IDE is atypical, and follows from its 
unusual structure, which consists of two bowl-shaped halves (dubbed IDE-N and 
IDE-C) connected by a flexible linker that, together, form a large (~30,000 Å3), 
completely enclosed internal chamber (Figure 10). Substrates and products can 
enter and leave, respectively, only when IDE adopts an “open” conformation; 
conversely, IDE is only proteolytically active when in the “closed” 
conformation161–163. Due to the size of the catalytic chamber, IDE can cleave only 
peptides of up to 70 amino acids. In addition, substrates make numerous contacts 
throughout the internal chamber, thereby influencing which peptide bonds are 
2.6.1 IDE substrates and its proteolytic activity   
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accessible to the active site; thus IDE does not show strong cleavage site 
specificity151. 
Interestingly, some researchers think that IDE is involved in the regulation of 
proteasomal degradation. According to these researchers, association of IDE 
with the proteasome causes an increase in proteasome activity, which is closely 
involved in protein metabolism and is controlled by hormones, as insulin 
action164,165. In their proposed scenario, insulin activates protein synthesis and 
inhibits protein degradation by the dissociation of the IDE-proteasome complex 
due to IDE binding to and degrading insulin internalized into the cytosol (a 
controversial idea). As a consequence, insulin degradation by IDE is predicted to 
induce the dissociation of the IDE-proteasome complex which leads to the 
inhibition of proteasome activity166. Once insulin degradation is produced, 
cytosolic IDE is reassociated with the proteasome (Figure 11). 
 
Figure 11: Schematic diagram of how insulin degradation acts to inhibit the proteasome167.  
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In order to clarify the physiological role of Ide and its links with T2DM, both 
invertebrate (e.g., Drosophila) and vertebrate (e.g., rodent) models have been 
developed and characterized. Genetic ablation of the Ide gene in Drosophila 
induced an increase of body weight and reduced blood glucose levels. In parallel, 
IDE overexpression resulted in body weight loss combined with an increase in 
blood glucose values168. 
A well-known diabetic rat model developed by selective breeding for 
hyperglycemia and glucose intolerance, known as the Goto-Kakizaki (GK) rat, 
was discovered to harbor two missense mutations in the IDE gene, one of which 
results in partial loss of proteolytic function, thus strengthening the association of 
the Ide locus with susceptibility to T2DM169. 
Mice with genetic deletion of Ide were first investigated by Farris et al.157 Life-
long, pancellular deletion (total knockout) of Ide in a combined genetic 
background (50% of C57BL/6 and 50% of 129SvEvBrd) at 4-8-months of age 
showed normal blood glucose levels, but exhibited pronounced glucose 
intolerance and hyperinsulinemia157. 
The IDE knockout mice studied by Farris et al., were characterized further by 
Abdul-Hay et al.170, this time in a complete C57BL/6 genetic background. Notably, 
these researchers conducted a longitudinal analysis, characterizing the same set 
of mice at 2, 4 and 6-months of age. As reported by Farris et al., , IDE knockout 
mice showed hyperinsulinemia at each time point. However, the glucose and 
insulin tolerance testing revealed a more complex, age-related phenotype. At 2-
months of age, IDE knock-out mice exhibited a trend to establish modestly 
improved glucose tolerance and insulin sensitivity relative to controls. However, 
this trend was lost at 6-months of age, by which time IDE total knock-out mice 
exhibited marked glucose intolerance and insulin resistance. These researchers 
also found that IR levels were reduced in several peripheral tissues (liver, skeletal 
muscle and adipose tissue)170. 
2.6.2 Animal models for the study of IDE 
 44 
 
Finally, the same animal model was once again analyzed by Steneberg et 
al.171, who conducted an extensive investigation of the mechanistic basis 
underlying the insulin intolerance observed in IDE total knock-out mice. The 
metabolic characterization of 2-month-old mice disclosed a strong glucose 
intolerance without insulin resistance or hyperinsulinemia171. Steneberg et al.171 
emphasized the importance of IDE in insulin secretion regulation, since their IDE 
total knock-out mice showed decreased insulin secretion by pancreatic β-cells171. 
Since the discovery of IDE in 1949 by I. Arthur Mirsky, it has been proposed 
that pharmacological inhibition of IDE might be a viable antidiabetic therapy. 
Assuming IDE is involved in the clearance of insulin, then in principle blocking 
the breakdown of insulin could boost insulin signaling. However, it would take 
more than 50 years before the first IDE inhibitors were developed, and inhibitors 
with sufficient properties to test this fundamental idea emerged only in the past 
few years172–175.  
Despite the intuitive appeal of this idea, we need to take into account that 
different studies suggested that a strong decrease of IDE activity will not have a 
beneficial impact in whole metabolism of T2DM patients. In theory, if IDE is 
involved in insulin clearance, than chronic inhibition of IDE might result in 
persistent hyperglycemia, which could in turn further increase insulin 
resistance176. Chronic hyperinsulinemia can also lead to up-regulation of cell 
proliferation177. Moreover, numerous side effects are expected after IDE 
inhibition, due to IDE degradation activity on other metabolic substrates as 
glucagon, Aβ and amylin. In the case of Aß, which accumulates abnormally in the 
brains of Alzheimer’s patients, it has been shown that inhibitors of IDE that do not 
cross the blood-brain barrier do not effect Aß173. However, with regard to amylin, 
which accumulates in the pancreas, there is controversy about possible 
exacerbation of amylin deposition due to IDE inhibition. On the one hand, using 
a weak inhibitor of IDE, bacitracin, which is also not very selective Bennett et 
al.178 reported that prolonged IDE inhibition leads to amyloid deposition178 in 
2.6.3 Pharmacological therapies against T2DM based on inhibition of IDE 
activity 
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cultured islets.  In contrast, using a much more potent and selective IDE inhibitor, 
Hogan et al.179 reported that IDE inhibition does not increase islet amyloid 
deposition179. Apart from amylin, however, IDE inhibition could impede glucagon 
degradation, intensifying glucose intolerance as a consequence of an increase in 
postprandial gluconeogenesis values180. Moreover, assuming the veracity of 
studies implicating IDE in proteasomal degradation, inhibition of intracellular IDE 
might deregulate proteasomal degradation and autophagic flux171,181 (Figure 12). 
 
Figure 12: Possible side effects of pharmacological IDE inhibition182. 
One of the most promising inhibitors of IDE is a highly potent and selective 
cyclic peptide known as 6bK, discovered and optimized by Maianti et al.173 Acute 
administration of 6bK decreased blood glucose levels in lean and obese mice 
after glucose challenge. However, insulin, glucagon and amylin circulating levels 
were increased during intraperitoneal glucose tolerance test (IPGTT) after 6bK 
dose administration. Despite these abnormal hormonal concentrations found 
during IPGTT; insulin, glucagon and amylin levels remained unaltered in basal 
conditions173. 
Durham et al.175 developed another IDE inhibitor, known as NTE-1. Rats 
treated with NTE-1 showed improved glucose tolerance despite presenting with 
elevated plasma amylin concentrations. Interestingly, however, NTE-1 treatment 
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did not produce significant differences on insulin and glucagon degradation in 
vivo179. 
Despite numerous studies linking IDE with T2DM, and despite IDE total-knock 
out mice having been generated and characterized, the role of IDE in the function 
of specific tissues remains unclear. To advance our understanding of the tissue-
specific functions of IDE, the work within this thesis is focused on physiological 
and pathophysiological roles of IDE specifically in liver. In particular, we have 
extensively characterized the consequences of genetic ablation of Ide exclusively 
in liver, in order to elucidate the role of IDE in hepatic function, hepatic glucose 
metabolism and hepatic insulin action. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hypotheses and Aims
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- Hepatic depletion of IDE impairs plasma insulin clearance in the liver of 
mice. 
- Genetic ablation of hepatic Ide causes insulin resistance and glucose 
intolerance in mice. 
- IDE regulates intracellular insulin signaling through a molecular 
mechanism that impairs insulin signal transduction at the post-receptor 
level in mouse hepatocytes. 
- To generate liver-specific Ide knockout (L-IDE-KO) mice by crossing the 
transgenic Albumin-Cre mouse and the IDEflox/flox mouse. 
- To assess plasma insulin clearance in L-IDE-KO and wild type (WT) mice. 
- To investigate glucose homeostasis in L-IDE-KO and WT mice 
(intraperitoneal glucose tolerance and insulin sensitivity). 
- To quantify gene expression of the gluconeogenic genes Pck1 and G6pc 
in the liver of L-IDE-KO and WT mice. 
- To reveal the impact of hepatic Ide ablation on lipid metabolism. 
- To analyze the impact of hepatic Ide ablation on intracellular insulin-
signaling pathway in L-IDE-KO and WT mice liver. 
3 HYPOTHESES AND AIMS 
3.1 Hypotheses 
3.2 Aims 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Material and Methods
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Mice were housed in ventilated cages on a 14-h light, 10-h dark schedule at 
the animal facility of the University of Valladolid (UVa, Spain). Cage enrichment 
included cotton bedding. Water and food were available ad libitum, consisting of 
normal mouse chow. Experimental procedures were approved by the Animal 
Care and Use Committee of the UVa in accordance with the European and 
Spanish Guidelines for the Care and Use of Mammals in Research (European 
Commission Directive 86/609/CEE and Spanish Royal Decree 1201/2005) – 
Protocol number JCyL #5003931.  
Power analysis to determine animal cohort numbers was based on preliminary 
results and previous literature. The B6.Cg-Tg(Alb-cre)21Mgn/J (Alb-Cre) mouse 
was purchased from Jackson Laboratory, USA. The IDEFlox/Flox mouse was kindly 
provided by Dr. Malcolm A. Leissring from the University of California, Irvine, 
USA. This mouse has loxP sites flanking exon 3 of the Ide gene. Cre 
recombinase-mediated deletion of exon 3 causes a frameshift with two stop 
codons in exon 4 and early termination of translation (Figure 13). 
 
Figure 13: Details of Ide gene deletion in L-IDE-KO mice. 
4 MATERIAL AND METHODS 
4.1 Animal procedures 
4.1.1 Animal facilities 
4.1.2 Breading strategies of liver-IDE knockout mice (L-IDE-KO) 
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To generate hepatocyte-specific IDE-KO, Alb-Cre mice were crossed to 
IDEFlox/Flox to generate IDEFlox/Flox;Alb-Cre/+, or their littermate controls IDEFlox/Flox;+/+ 
(Figure 14). 
 
Figure 14: Breeding strategy for developing and maintaining the L-IDE-KO mouse colony. 
The experimental cohorts used in this study were males and females of the F3 
generation. The F1 generation was composed of heterozygous IDEFlox/+;Alb-Cre/+ 
and WT IDEFlox/Flox;+/+, from crosses of IDEFlox/Flox;+/+ and IDE+/+;Alb-Cre/+ in the 
parental generation. 
4.2 Experimental animals 
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F2 generation was composed of WT IDEFlox/Flox;+/+, IDEFlox/+;+/+, heterozygous 
IDEFlox/+;Alb-Cre/+ and L-IDE-KO IDEFlox/Flox;Alb-Cre/+ from crosses of heterozygous 
IDEFlox/+;Alb-Cre/+ and IDEFlox/Flox;+/+.  
In order to obtain only WT (IDEFlox/Flox;+/+) and L-IDE-KO (IDEFlox/Flox;Alb-Cre/+), F3 
generation was generated from crosses between L-IDE-KO F2 generation 
(IDEFlox/Flox;Alb-Cre/+) and WT (IDEFlox/Flox;+/+) (Figure 14). 
Twenty independent cohorts were used for the metabolic studies and 
collection of tissues in this work. Males and females were characterized at 1 and 
3 months of age. 
DNA for genotyping was extracted from tails. Briefly, a tail snip of ~0.3-0.5 cm 
was incubated in 50 µL of Quick Extract (Epicentre, USA) at 65 ºC for 8 min, 
followed by mixing by vortex for 10 to 15 s. Afterwards, samples were incubated 
2 min at 98 ºC, followed by 10-15 s mixing by vortex, and frozen at -20 ºC until 
its use. 
The PCR reaction preparation is listed in Table 5. The PCR reaction master 
mix was scaled up according the samples number.  
 
Table 5: PCR master mix reagents for the setup of one reaction. 
4.3 Mouse genotyping 
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Three different genes were routinely distinguished by PCR analysis. GAPDH 
was used as a control for the quality of DNA extraction, Ide and Alb-Cre were 
detected by using the primers showed in Table 6. In Table 7, 8 and 9 are 
described the PCR conditions for GAPDH, Ide and Alb-Cre genes respectively. 
 
Table 6: Primer sequences used for mouse genotyping and the sizes of resulting amplicons. 
 
Table 7: PCR conditions for amplification of GAPDH. 
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Table 8: PCR conditions for amplification of IDE. 
 
Table 9: PCR conditions for amplification of Alb-Cre. 
To visualize PCR products, samples were mixed with DNA-loading buffer 
(Bioline, UK) and loaded into 1% agarose gels (for GAPDH and IDE) or on 2% 
agarose gels (for Alb-Cre). Afterwards, samples were run at 120V for 
approximately half an hour in 1X TBE buffer (89 mM Tris-HCl, pH 7.6, 89 mM 
boric acid and 2 mM EDTA). Finally, agarose gels were stained with 2.5 µL red 
safe (iNtRON Biotechnology, South Korea) and visualized on a shortwave UV 
radiation transiluminator (Figure 15). 
 58 
 
 
Figure 15: Representative image of mouse genotyping. On the left are depicted the molecular sizes of 
the amplicons (base pairs). 
Body weight was monitored periodically using a digital weight scale (Adam 
Equipment, USA). 
For food intake determination, L-IDE-KO and WT mice were separated in 
individual cages (n = 7-11 mice per genotype). After 15 h fasting, food pellets (40 
g) were added to each cage; and the food intake of each mouse was estimated 
from the difference in remaining food weight 24 h later. These weights were 
averaged to provide an estimate of the mean food intake of each genotype in 24 
h. 
For obtaining blood, 1-2 mm of tissue was cut from the tail tip with a scalpel 
(Romed, Holland). Then, blood was obtained by direct flow or by gently 
massaging (“milking”) the tail and collecting the blood in a capillary tube coated 
with potassium-EDTA (Microvette, Stardest, Germany). 
4.4 Metabolic characterization 
4.4.1 Body weight 
4.4.2 Food intake 
4.4.3 Blood sampling 
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To acquire plasma, blood samples (50-100 µL) obtained as described above, 
were centrifuged at 2600 X g for 10 min at room temperature. Afterwards, plasma 
was transferred into a clean polypropylene tube using a micropipette. The 
samples were kept on ice and then stored at -20 ºC. 
Blood glucose levels were determined using a Breeze 2 glucometer (Bayer, 
Germany). Blood glucose measurements were performed in mice under fasting 
or non-fasting conditions. Fasting conditions are considered as a period of 14-16 
h without food and non-fasting conditions are considered just after the dark 
schedule, at 8:00 a.m. 
The HOMA index is a method used to quantify insulin resistance. This index is 
overnight fasting blood glucose levels x fasting plasma insulin levels/22.5. The 
normal HOMA value of healthy humans ranges from 1.5-2.0; however, values 
above 2.0 indicates significant insulin resistance183. In mice, there is not a HOMA 
cut off value; in practice, insulin resistance is determined by comparing HOMA 
values obtained from experimental mice to their control littermates. This index 
was first described under the name HOMA by Matthews et al. in 1985184. 
In our study, data were analyzed by HOMA Calculator software (University of 
Oxford, United Kingdom). 
Insulin levels were assessed employing the Ultrasensitive Mouse and Human 
Insulin enzyme-linked immunosorbent assay (ELISA) kit (Mercodia, Sweden), 
using 10 µL of mouse plasma. This ELISA is a solid-phase two-site enzyme 
immunoassay. It is based on the direct sandwich technique in which two 
monoclonal antibodies are directed against separate antigenic determinants on 
4.4.4 Plasma collection 
4.4.5 Blood glucose levels 
4.4.6 Homeostatic Model Assessment (HOMA) index 
4.4.7 Plasma insulin levels 
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the insulin molecule (Figure 16). Insulin in the plasma sample binds to anti-insulin 
antibodies attached to the microtitration well and the quantity is detected using 
another peroxidase-conjugated anti-insulin antibody. A simple washing step 
removes unbound enzyme-labeled antibody.  The bound conjugate is detected 
by reaction with TMB (3,3’,5,5’-tetramethylbenzidine). The reaction is stopped by 
adding acid to give a colorimetric endpoint that is read spectrophotometrically at 
a wavelength of 450 nm using a microplate reader (Heales, China). The intensity 
of this colored product is directly proportional to the concentration of insulin 
present in the original specimen. The concentration in plasma samples can be 
determined by conversion of the values of absorbance using a standard curve. 
 
Figure 16: Illustration of insulin detection using the ELISA technique. 
Glucagon levels were assessed employing the glucagon ELISA kit (Mercodia, 
Sweden), using 10 µL of mouse plasma. This glucagon ELISA kit recognizes 
glucagon from mouse, rat and human origin. This ELISA is a solid-phase two-site 
enzyme immunoassay. It is based on the direct sandwich technique in which two 
monoclonal antibodies are directed against separated antigenic determinants on 
the glucagon molecule (Figure 17). Glucagon in the plasma sample binds to anti-
glucagon antibodies (clone M5F9S) attached to microplate wells and are 
4.4.8 Plasma glucagon levels 
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detected by a different peroxidase-conjugated anti-glucagon antibody (clone 
E6A11K). A simple washing step removes unbound enzyme labelled antibody. 
The bound conjugate is detected by reaction with TMB. The reaction is stopped 
by adding acid to give a colorimetric endpoint that is read spectrophotometrically 
at a wavelength of 450 nm using a microplate reader (Heales, China). The 
intensity of this colored product is directly proportional to the concentration of 
glucagon present in the original specimen. A standard curve of known 
concentration can be established accordingly. The unknown concentration in 
samples can be determined by reference to this standard curve. 
 
Figure 17: Illustration of glucagon detection using the ELISA technique. 
Aβ40 levels were assessed employing the Mouse Aβ40 ELISA kit (Invitrogen, 
USA), using 100µL of mouse plasma. This ELISA is a solid-phase sandwich-
based assay. A monoclonal antibody of mouse Aβ has been coated onto the wells 
of the microtiter strips. Samples, including standards of known mouse Aβ40 
content, are pipetted into these wells. The Aβ40 antigen binds to the immobilized 
antibody. After washing, a rabbit antibody specific for the 1-40 Aβ sequence is 
added to the wells. Bound rabbit antibody is detected by the use of a horseradish 
peroxidase-labeled anti-rabbit antibody. After removal excess of anti-rabbit 
4.4.9 Plasma Aβ40 levels 
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antibody, a substrate solution is added and it reacts to the bound enzyme to 
produce color (Figure 18). The microplate is read spectrophotometrically at a 
wavelength of 450 nm using a microplate reader (Heales, China). The intensity 
of this colored product is directly proportional to the concentration of Mouse Aβ40 
present in the original specimen. A standard curve of known concentration can 
be established accordingly. The unknown concentration in samples can be 
determined by extrapolation to this standard curve. 
 
Figure 18: Illustration of Aβ40 detection using the ELISA technique. 
Amylin levels were assessed employing the mouse amylin enzyme 
immunoassay (EIA) kit (Phoenix Pharmaceuticals, USA), using 50 µL of mouse 
plasma. The immunoplate in this kit is pre-coated with secondary antibody and 
the nonspecific binding sites are blocked. The secondary antibody can bind to 
the crystallizable fragment (Fc) region of the primary antibody whose antigen-
binding fragment (Fab) site will be competitively bound by both biotinylated 
peptide and standard peptide or targeted peptide in samples. The biotinylated 
peptide interacts with streptavidin-horseradish peroxidase (SA-HRP) which 
catalyzes the substrate solution (Figure 19). The microplate is read 
spectrophotometrically at a wavelength of 450 nm using a microplate reader 
4.4.10 Plasma amylin levels 
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(Heales, China). The intensity of the yellow is directly proportional to the amount 
of biotinylated peptide-SA-HRP complex but inversely proportional to the amount 
of the peptide in standard solutions or samples. This is due to the competitive 
binding of the biotinylated peptide with the standard peptide or samples to the 
peptide antibody (primary antibody). A standard curve of known concentration 
can be established accordingly. The unknown concentration in samples can be 
determined by reference to this standard curve. 
 
Figure 19: Illustration of amylin detection using the competitive ELISA technique. 
Triglycerides levels were assessed employing the triglycerides colorimetric kit 
(Biosystems, Spain), using 3 µL of mouse plasma. Triglycerides in the samples 
result in, by means of coupled reactions (Figure 20), a colored complex that can 
be measured by spectrophotometry at a wavelength of 500 nm using a microplate 
reader (Heales, China). The intensity of this colored product is directly 
proportional to the concentration of triglycerides present in the original specimen. 
A standard curve of known concentration can be established accordingly. The 
unknown concentration in samples can be determined by reference to this 
standard curve. 
4.4.11  Plasma triglycerides levels 
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Figure 20: Principle of the method to assess plasma triglycerides levels. 
Cholesterol levels were assessed employing the cholesterol colorimetric kit 
(Biosystems, Spain), using 3 µL of mouse plasma. Free and esterified cholesterol 
in the samples results in, by means of the coupled reactions (Figure 21), a 
colored complex that can be measured by spectrophotometry at a wavelength of 
500 nm using a microplate reader (Heales, China). The intensity of this colored 
product is directly proportional to the concentration of free and esterified 
cholesterol present in the original specimen. A standard curve of known 
concentration can be established accordingly. The unknown concentration in 
samples can be determined by reference to this standard curve. 
 
Figure 21: Principle of the method to assess plasma cholesterol levels. 
NEFFAs were assessed employing the NEFFA-HR(2) kit (Wako, Germany), 
using 5 µL of mouse plasma. The contents of one flask of “reagent A” were 
dissolved with 50 mL of “buffer A” to obtain “solution A”. “Solution B” was 
prepared by dissolving the contents of one flask of “reagent B” with 25 mL of 
“buffer B”. 5 µL of mouse plasma were sampled and mixed with 200 µL of 
4.4.12  Plasma cholesterol levels 
4.4.13  Plasma Non-Esterified Free Fatty Acids (NEFFAs) levels 
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“solution A” and incubated at 37 ºC for 5 min. Thereafter, 100 µL of “solution B” 
was added and incubated for 5 min at 37 ºC. After the second incubation period, 
the microplate was read spectrophotometrically at a wavelength of 562 nm using 
a microplate reader (Heales, China). The intensity of this colored product is 
directly proportional to the concentration of NEFFAs present in the original 
specimen. A standard curve of known concentration can be established 
accordingly. The unknown concentration in samples can be determined by 
extrapolation to this standard curve. 
The principle of the method and the chemical reactions occurring in this 
process are described in Figure 22. 
 
Figure 22: Principle of the method to assess plasma non-esterified free fatty acids levels. 
To evaluate alterations in glucose homeostasis in vivo, we performed 
intraperitoneal glucose tolerance test (IPGTT) when mice were 1 and 3 months 
old. Mice were fasted overnight from 6 p.m. to 9 a.m.  Glucose (Merck, USA) at 
2 g/kg body weight was injected into the intraperitoneal cavity. Blood glucose 
levels were measured before glucose challenge (time 0) and 15, 30, 60 and 120 
min after glucose injection using a Breeze 2 glucometer (Bayer, Germany). 
The area under the curve (AUC) is the area between the graph and the X-axis, 
it is given by the definite integral below. A definite integral has start and end 
values: in this case, time 0 and time 120 minutes.  
4.4.14  Glucose tolerance test (GTT) 
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To evaluate insulin action in vivo, we performed intraperitoneal insulin 
tolerance test (IPITT) when mice were 1 and 3 months old. Mice were in non-
fasted conditions. Human insulin (Humulin; Lilly, USA) at a dose of 0.75 U/kg 
body weight was injected intraperitoneally in mice. Blood glucose levels were 
monitored before insulin injection (time 0) and 15, 30, 60, 90, 120, 240 min after 
insulin injection using a Breeze 2 glucometer (Bayer, Germany). 
The area under the curve (AUC) is the area between the graph and the X-axis, 
it is given by the definite integral below. A definite integral has start and end 
values: in this case, time 0 and time 240 minutes. 
To evaluate alterations in hepatic glucose production in vivo, we performed 
intraperitoneal pyruvate tolerance test (IPPTT) when mice were 3 months old. 
Mice were fasted overnight from 6 p.m. to 9 a.m.  Pyruvate (Sigma, USA) at 2 
g/kg body weight was injected into the intraperitoneal cavity. Blood glucose levels 
were measured before pyruvate injection (time 0) and 15, 30, 60 and 120 min 
after pyruvate injection using a Breeze 2 glucometer (Bayer, Germany). 
The area under the curve (AUC) is the area between the graph and the X-axis, 
it is given by the definite integral below. A definite integral has start and end 
values: in this case, time 0 and time 120 min. 
3-month-old mice were fasted for 2 h (from 8 a.m. to 10 a.m.) and then 
anesthetized using a solution of medetomidine + ketamine at 0,125m-k/100 g 
body weight. Afterwards, human insulin (Humulin; Lilly, USA) was injected intra-
orbitally at 1 nmol/kg. Immediately after injection, timing was started and blood 
samples were collected from the tail vein 0, 5, 10, 20, 30 and 60 min after insulin 
administration. These samples were prepared as described in section 4.4.4 and 
used for determination of human plasma insulin levels. 
4.4.15 Insulin tolerance test (ITT) 
4.4.16 Pyruvate tolerance test (PTT) 
4.4.17 In vivo insulin clearance 
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Liver glycogen content was assessed employing the glycogen content assay 
kit (Sigma, USA), an enzymatic colorimetric assay. 
Liver samples (10 mg) were homogenized in 100 µL ultrapure water 
supplemented with protease and phosphatase cocktail inhibitors (Sigma, USA) 
on ice. Homogenates were boiled at 100 ºC for 5 min to inactivate enzymes and 
centrifuged 5 min at 12300 X g at room temperature to remove insoluble 
materials. 
Liver homogenates were collected and diluted 1:100 in duplicate in hydrolysis 
buffer up to a final volume of 50 µL. To one of the duplicates 2 µL of hydrolysis 
enzyme mix were added; while, to the other duplicates 2 µL of ultrapure water 
were added. These last samples were used as controls of hepatic glucose 
content in each liver. After that, the microplate was incubated for 30 min at room 
temperature. Then, 50 µL of master reaction mix, which contains the 
development buffer (46 µL), the development enzyme mix (2 µL) and the 
fluorescent peroxidase substrate (2 µL), was added to each well and incubated 
for 30 min at room temperature. During the reaction incubation, the plate was 
protected from light. Finally, the microplate was read spectrophotometrically at a 
wavelength of 562 nm using a microplate reader (Heales, China). The intensity 
of this colored product is directly proportional to the concentration of glycogen 
present in the original specimen. A standard curve of known concentration can 
be established accordingly. The unknown concentration in samples can be 
determined by reference to this standard curve. 
As a general procedure, mice were euthanized using cervical dislocation or by 
CO2 inhalation. For those experiments that required insulin signaling activation, 
3-month-old mice were fasted overnight from 6 p.m. to 9 a.m. Then, mice were 
injected intraperitoneally with human insulin (Humulin; Lilly, USA) at a dose of 
0.75 U/kg body weight or with saline solution.  After 10 min, mice were 
4.4.18  Liver glycogen content 
4.5 Tissue dissection 
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anesthetized with isoflurane atmosphere, followed by exsanguination and tissues 
removal. Blood and plasma samples were prepared and stored as described in 
section 1.5.4.  
Liver, white adipose tissue (WAT), brain, lungs, kidneys, heart, soleus and 
gastrocnemius muscles were removed and snap frozen in liquid nitrogen and 
stored at -80 ºC until analysis. 
Protein lysates from animal tissues were prepared by homogenizing the 
tissues in lysis buffer (Cell signaling, USA) supplemented with protease and 
phosphatase cocktail inhibitors (Sigma, USA). Lysates were sonicated for 20 min 
on ice, and were centrifuged at 18500 X g for 10 min at 4 ºC to separate and 
discard insoluble materials. Supernatants were kept and quantified for protein 
content using the Pierce BCA proteins assay kit (Thermo-Fisher, USA). 
For the extraction of membrane proteins from liver tissues, we used the Plus 
Membrane Protein Extraction Kit (Thermo-Fisher, USA) following manufacturer’s 
instructions. Briefly, to separate cytosolic and membrane fractions 30 mg of liver 
was cut and washed with the Cell Wash Solution, transferred to a glass tissue 
grinder where it was homogenized by 6-10 strokes and incubated 10 min at 4 ºC 
with constant mixing. Lysates were centrifuged at 18500 X g for 15 min at 4 ºC to 
separate cytosolic (supernatant) and membrane (pellet) fractions. Subsequently, 
supernatant was removed and pellet was resuspended in Solubilization Buffer by 
pipetting, incubated 40 min at 4 ºC with constant mixing and centrifuged at 18500 
X g for 15 min at 4 ºC. The supernatant, which contains the membrane and 
membrane-associated proteins, was tranferred to a new tube. Again, proteins 
were quantified by Pierce BCA proteins assay kit (Thermo-Fisher Scientific, 
USA). Afterwards, 40 µg of protein from the tissue lysate soluble fraction were 
boiled 5 min in Laemmli Sample Buffer (LSB) (62.5 mM Tris-HCl, 5% glycerol, 
1% SDS, 2.5% β-mercaptoethanol and 0.02% w/v bromophenol blue). Protein 
samples were separated by their molecular weight using 10% SDS-PAGE 
4.6 Western blot 
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precast polyacrylamide gel (Criterion Tris-HCl protein gel, Bio Rad, USA) and 
electro-transferred onto polyvinylidene difluoride filters (PVDF; Millipore, USA) for 
immunoblotting by conventional means. Electro-transferred PVDF membranes 
were blocked for 1 h at room temperature using blocking buffer (1X PBS, 0.1% 
Tween-20 with 5% w/v non-fat dry milk). After being probed with specific 
antibodies, the membranes were stripped using stripping buffer (2% SDS, 
62.5mM Tris-HCl, pH 6.8 and 100mM β-mercaptoethanol) for 30 min at 50 ºC 
and then washed and reprobed with other antibodies. Signals were detected by 
chemiluminescence (Clarity Western ECL Substrate kit; Bio Rad, USA) and band 
densitometry was quantified with Image J software (National Institutes of Health, 
USA).  
A list of the antibodies, dilutions and incubation times used in this work is 
provided in Table 10 and 11. 
 
Table 10: List of primary antibodies.  
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Table 11: List of secondary antibodies. 
Tissues obtained from L-IDE-KO and WT mice were lysed in 1 mL of Trizol 
(Invitrogen Life Technologies, USA) by micro tissue homogenizer. Following 
homogenization, samples were incubated for 5 min at room temperature, to 
complete the dissociation of nucleoprotein complexes, and centrifuged at 10500 
X g for 10 min at 4 ºC to remove insoluble material from the homogenate. The 
resulting pellet contained extracellular membranes and high molecular weight 
DNA, while the supernatant contained RNA. This supernatant was transferred to 
a new tube. Then, 200 µL of chloroform (PanReac AppliChem, Germany) was 
added, and samples were incubated 2-3 min at room temperature after a vigorous 
shaking by hand. Samples were centrifuged at 10500 X g for 15 min at 4 ºC and 
consequently the mixture was separated in 3 different phases: a lower red phase 
rich in proteins, a deep red interphase rich in DNA, and a colorless or aqueous 
phase rich in RNA. The aqueous phase was transferred to a new tube. 
Afterwards, 500 µL of isopropyl alcohol (PanReac AppliChem, Germany) was 
added to precipitate the RNA from the aqueous phase. Samples were mixed 
vigorously by hand, incubated 15 minutes at room temperature and centrifuged 
at 10500 X g for 10 min at 4 ºC. The RNA precipitate forms a pellet on the side 
and bottom of the tube. The supernatant was removed. In order to wash the RNA 
obtained, 1 mL of 75% ethanol was added to each sample, mixed vigorously by 
hand and centrifuged at 4000 X g for 5 min at 4 ºC. At the end of this procedure, 
supernatants were removed and the RNA pellet was air-dried for 20 min. Finally, 
RNA was dissolved in RNase-free water and incubated for 5 min at 60 ºC. The 
amount of RNA from each sample was quantified by NanoDrop (Thermo-Fisher 
Scientific, USA) using 1 µL of sample (Figure 23). 
4.7 RNA isolation and cDNA synthesis 
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Figure 23: Representative illustration of RNA quantification by NanoDrop. 
Once RNA isolation was completed, DNA residues were removed by RapidOut 
DNA removal kit (Thermo-Fisher Scientific, USA), which ensured complete 
digestion of DNA without RNA damaging. First, RNA sample was treated with 
recombinant DNase-I 30 min at 37 ºC. Second, DNase-I was safely removed 
using DNase removal reagent, which binds DNase-I, allowing the complex to be 
pelleted by centrifugation. The purified RNA was collected in the supernatant 
fraction. 
To perform cDNA synthesis from RNA, iScript cDNA synthesis kit (Bio Rad, 
USA) was used, which is a sensitive, fast, and convenient reagent for gene 
expression analysis using real-time reverse transcription quantitative PCR (RT-
qPCR). To carry out the reverse transcription reaction, a mixture was made as 
indicated in the Table 12. 
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Table 12: Reverse transcription reaction mix. 
Once the reaction mixture was prepared, was incubated in the 2720 thermal 
cycler (Applied Biosystems, USA) using the following protocol (Table 13) to 
obtain the cDNA necessary to carry out the RT-qPCR. 
 
Table 13: Thermocycler retro-transcription reaction protocol. 
Prior to initiate the RT-qPCR, a PCR master mix solution was prepared as 
shown in Table 14.  
4.8 RT-qPCR 
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Table 14: RT-qPCR master mix reagents for one reaction. 
mRNA levels were determined by RT-qPCR with TaqMan® probes (Applied 
Biosystems, USA) using a Rotor-Gene 3000 thermocycler (Corbett Life Science, 
USA). Data were analyzed with the threshold cycle relative quantification method 
(∆∆Ct) and normalized to an endogenous control (ribosomal protein L18). 
TaqMan assays were used for Ide, Pck1 and G6pc (Applied Biosystems, USA) 
genes. 
Statistical analysis of data was performed using the GraphPad Prism Software 
6.0 (CA, USA). Distributions were checked with the Kolmogorov-Smirnov test. 
Data are presented as means ± SEM. Homogeneity of variance was performed 
using the Levene test. Comparisons between two groups were done using the 
unpaired Students´ T-test (if homogeneity of variance) or the Welch test (if 
heterogeneity of variance) when a variable was distributed normally; in the case 
of a non-parametric variable the Mann-Whitney U-test was used. Comparisons 
between more than two groups were done using the one-way ANOVA or the 
Kruskal-Wallis test when a variable was distributed normally or non-normally, 
respectively. For post-hoc analyses the Bonferroni test or Durnett test was used 
if homogeneity or heterogeneity of variance respectively. Differences were 
considered significant at p<0.05. 
4.9 Statistical analysis 
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To ablate Ide in hepatocytes, we bred mice homozygous for a floxed Ide allele 
(Dr. Malcolm Leissring, University of California, Irvine) with albumin-Cre mice 
(Jackson Laboratory, USA). Hereafter, these mice will be named L-IDE-KO. 
Hepatic Ide mRNA levels (Figure 24) and protein (Figure 25) levels were 
decreased by ~90-95% in L-IDE-KO mice, compared to controls. 
 
Figure 24: Expression levels of Ide in L-IDE-KO and WT mice. Expression of Ide in 3-month-old L-
IDE-KO and their littermate WT male mice. Tissues from L-IDE-KO and WT mice were collected and mRNA 
isolated.  RT-qPCR was performed as described in Material and Methods section. All samples were 
normalized by the L18 mRNA. mRNA expression levels are represented as mean ± SEM. n=4 per genotype. 
* p value < 0.05 vs. WT by Students´ T-test. 
 
Figure 25: IDE levels in the liver of L-IDE-KO, Total-IDE-KO and WT mice. Representative western 
blots of liver lysates (40 µg protein/sample) isolated from 3-month-old L-IDE-KO, Total-IDE-KO and WT mice 
using anti-IDE and anti-actin antibodies. n= 2 per genotype. 
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Surprisingly, RT-qPCR analysis showed higher mRNA expression levels in 
skeletal muscle of L-IDE-KO in comparison to WT mice (Figure 24). However, 
this increase did not affect IDE protein expression levels, as it is shown by 
western blot analysis (Figure 26). 
 
Figure 26: IDE levels in the skeletal muscle of L-IDE-KO and WT male mice. (A) Representative 
western blots of skeletal muscle lysates (40 µg protein/sample) isolated from 3-month-old L-IDE-KO and WT 
male mice using anti-IDE and anti-Actin antibodies. (B) Relative amounts of IDE, after normalizing to actin. 
n= 6 per genotype. Data are mean ± SEM. 
In order to clarify the role of hepatic IDE on the hepatic glucose metabolism, 
and the relationship between hepatic IDE function and the development of T2DM, 
we performed a metabolic characterization of L-IDE-KO mice. 
Metabolic characterization of the L-IDE-KO and WT mice began with the 
analysis of blood glucose levels after prolonged (15 h) fasting. These 
measurements were done at 1 and 3 months of age in both sexes. Fasting blood 
glucose levels were similar in 1-month-old female L-IDE-KO and WT mice. 
However, at 3 months of age, L-IDE-KO female mice exhibited higher blood 
glucose levels (Figure 27) 
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Figure 27: Fasting blood glucose levels of L-IDE-KO and WT female mice. Blood glucose 
measurements were obtained after an overnight fasting at 1 and 3 months of age. n= 11-21 per genotype. 
Data are mean ± SEM. * p < 0.05 vs. WT by Students’ T-test. 
In contrast, 1-month-old male L-IDE-KO mice displayed lower fasting glucose 
levels than littermate controls (Figure 28). Surprisingly, at 3 months of age, 
L-IDE-KO male mice exhibited higher glucose levels than WT mice (Figure 28). 
Taken together, these results indicate that 3-month-old male and female 
L-IDE-KO mice have higher blood glucose levels than WT mice.  
 
Figure 28: Fasting blood glucose levels of L-IDE-KO and WT male mice. Blood glucose 
measurements were obtained after an overnight fasting at 1 and 3 months of age. n= 8-15 per genotype. 
Data are mean ± SEM. * p < 0.05 vs. WT by Students’ T-test. 
An increase in body weight can result in higher blood glucose levels. To reveal 
whether or not body weight is related to the observed alterations in blood glucose 
levels, 1- and 3-month-old male and female mice were weighed. As shown in 
Figure 29 and 30, body weight remained unchanged between L-IDE-KO and 
their littermates WT mice.  
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Figure 29: Fasting body weight of L-IDE-KO and WT female mice. Body weight measurements were 
monitored after an overnight fasting at 1 and 3 months of age. n= 11-21 per genotype. Data are mean ± 
SEM. 
 
Figure 30: Fasting body weight of L-IDE-KO and WT male mice. Body weight measurements were 
monitored after an overnight fasting at 1 and 3 months of age. n= 8-15 per genotype. Data are mean ± SEM. 
In non-fasting conditions, 1- and 3-month-old L-IDE-KO female mice showed 
similar blood glucose levels compared to WT mice (Figure 31). Likewise, body 
weight remained unchanged between L-IDE-KO and their littermate WT mice 
(Figure 32). 
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Figure 31: Non-fasting blood glucose levels of L-IDE-KO and WT female mice. Blood glucose 
measurements were obtained in non-fasting conditions at 1 and 3 months of age. n= 11-21 per genotype. 
Data are mean ± SEM. 
 
Figure 32: Non-fasting body weight of L-IDE-KO and WT female mice. Body weight measurements 
were monitored in non-fasting conditions at 1 and 3 months of age. n= 11-21 per genotype. Data are mean 
± SEM. 
On the other hand, 1- and 3-month-old L-IDE-KO male mice showed a 
significant increase in non-fasting glucose levels compared to WT mice (Figure 
33). This phenotype in glucose homeostasis was independent of body weight 
(Figure 34) or food intake (Figure 35). 
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Figure 33: Non-fasting blood glucose levels of L-IDE-KO and WT male mice. Blood glucose 
measurements were obtained in non-fasting conditions at 1 and 3 months of age. n= 8-15 per genotype. 
Data are mean ± SEM. * p < 0.05 vs. WT by Students´ T-test. 
 
Figure 34: Non-fasting body weight of L-IDE-KO and WT male mice. Body weight measurements 
were monitored in non-fasting conditions at 1 and 3 months of age. n= 8-15 per genotype. Data are mean ± 
SEM.  
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Figure 35: Caloric intake in L-IDE-KO and WT male mice. Food intake measurements in 3-month-old 
male mice were obtained as described in the Materials and Methods after an overnight fasting. n= 6 per 
genotype. Data are mean ± SEM. 
Glucose homeostasis was analyzed in L-IDE-KO and WT mice by an IPGTT 
at 1 and 3 months of age. 
L-IDE-KO female mice exhibited glucose intolerance at 1 month of age (Figure 
36) compared to WT mice. Of note, the phenotype persisted at 3 months of age. 
(Figure 37). 
 
Figure 36: IPGTT of 1-month-old L-IDE-KO and WT female mice. (A) 1-month-old L-IDE-KO and WT 
female mice were intraperitoneally injected with a bolus of glucose at a dose of 2 g/kg of body weight after 
an overnight fasting. Glucose measurements were done at the indicated times. (B) AUC of IPGTT. n= 11-
13 per genotype. Data are mean ± SEM. * p < 0.05 vs. WT by Students´ T-test. 
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5.2.3 Hepatic Ide ablation impairs glucose tolerance in L-IDE-KO mice  
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Figure 37: IPGTT of 3-month-old L-IDE-KO and WT female mice. (A) 3-month-old L-IDE-KO and WT 
female mice were intraperitoneally injected with a bolus of glucose at a dose of 2 g/kg of body weight after 
an overnight fasting. Glucose measurements were done at the indicated times. (B) AUC of IPGTT. n= 12-
21 per genotype. Data are mean ± SEM. * p < 0.05 vs. WT by Students´ T-test. 
On the other hand, 1-month-old L-IDE-KO male mice exhibited similar glucose 
tolerance compared to WT mice (Figure 38). 
However, at 3 months of age, L-IDE-KO male mice exhibited a robust 
phenotype of glucose intolerance compared to WT mice (Figure 39).  
 
Figure 38: IPGTT of 1-month-old L-IDE-KO and WT male mice. (A) 1-month-old L-IDE-KO and WT 
male mice were intraperitoneally injected with a bolus of glucose at a dose of 2g/kg of body weight after an 
overnight fasting. Glucose measurements were done at the indicated times. (B) AUC of IPGTT. n= 8-15 per 
genotype. Data are mean ± SEM. * p < 0.05 vs. WT by Students´ T-test. 
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Figure 39: IPGTT of 3-month-old L-IDE-KO and WT male mice. (A) 3-month-old L-IDE-KO and WT 
male mice were intraperitoneally injected with a bolus of glucose at a dose of 2 g/kg of body weight after an 
overnight fasting. Glucose measurements were done at the indicated times. (B) AUC of IPGTT. n= 8-10. 
Data are mean ± SEM. * p < 0.05 vs. WT by Students´ T-test. 
Taken together, these data indicate that hepatic deletion of Ide in male and 
female mice results in impaired glucose tolerance and higher blood glucose 
levels at 3 months of age. 
To further explore the phenotype of altered glucose homeostasis observed in 
L-IDE-KO mice, we investigated insulin sensitivity. To this end, 1- and 3-month-
old male and female mice underwent an IPITT. 
At 1 and 3 months of age, L-IDE-KO female mice exhibited marked insulin 
resistance in comparison to WT mice (Figure 40 and 41).  
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5.2.4 Hepatic Ide ablation causes insulin resistance in L-IDE-KO mice 
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Figure 40: IPITT in 1-month-old L-IDE-KO and WT female mice. (A) 1-month-old L-IDE-KO and WT 
female mice were injected with a bolus of insulin (0.75U/kg of body weight). Glucose measurements were 
performed at the indicated times. (B) AUC of IPITT. n= 11-13 per genotype. Data are mean ± SEM. * p < 
0.05 vs. WT by Students´ T-test. 
 
Figure 41: IPITT in 3-month-old L-IDE-KO and WT female mice. (A) 3-month-old L-IDE-KO and WT 
female mice were injected with a bolus of insulin (0.75U/kg of body weight). Glucose measurements were 
performed at the indicated times. (B) AUC of IPITT. n= 11-20 per genotype. Data are mean ± SEM. * p < 
0.05 vs. WT by Students´ T-test. 
In contrast, 1-month-old L-IDE-KO male mice exhibited mild but statistically 
significant insulin resistance (Figure 42). However, at 3 months of age, L-IDE-
KO male mice showed marked insulin resistance (Figure 43). 
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Figure 42: IPITT in 1-month-old L-IDE-KO and WT male mice. (A) 1-month-old L-IDE-KO and WT 
male mice were injected with a bolus of insulin (0.75 U/kg of body weight). Glucose measurements were 
performed at the indicated times. (B) AUC of IPITT. n= 8-15 per genotype. Data are mean ± SEM. * p < 0.05 
vs. WT by Students´ T-test. 
 
Figure 43: IPITT in 3-month-old L-IDE-KO and WT male mice. (A) 3-month-old L-IDE-KO and WT 
male mice were injected with a bolus of insulin (0.75 U/kg of body weight). Glucose measurements were 
performed at the indicated times. (B) AUC of IPITT. n= 12-13 per genotype. Data are mean ± SEM. * p < 
0.05 vs. WT by Students´ T-test. 
Taken together, these data indicate that hepatic deletion of Ide in L-IDE-KO 
male and female mice results in impaired insulin sensitivity at 1 and 3 months of 
age, which are in good agreement with a phenotype of glucose intolerance. 
To gain further insights into the metabolic phenotype of L-IDE-KO mice, we 
next investigated fasting and non-fasting plasma insulin levels. As shown in 
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Figure 44, plasma insulin levels in 1 and 3-month-old L-IDE-KO female mice 
remaining unchanged, compared to WT mice.  
 
Figure 44: Plasma insulin levels in L-IDE-KO and WT female mice. (A) Fasting plasma insulin levels 
in 1- and 3-month-old L-IDE-KO and WT female mice were assessed as described in the Material and 
Methods section. n= 11-23 per genotype. (B) Non-fasting plasma insulin levels in 1- and 3-month-old L-IDE-
KO and WT female mice. n= 11-23 per genotype. Data are mean ± SEM.  
Likewise, no differences in plasma insulin levels were observed in L-IDE-KO 
male mice under fasting (Figure 45.A) or non-fasting (Figure 45.B) conditions at 
1 and 3 months of age. 
 
Figure 45: Plasma insulin levels in L-IDE-KO and WT male mice. (A) Fasting plasma insulin levels in 
1- and 3-month-old L-IDE-KO and WT male mice were assessed as described in the Material and Methods 
section. n= 8-15 per genotype. (B) Non-fasting plasma insulin levels in 1- and 3-month-old L-IDE-KO and 
WT male mice. n= 8-15 per genotype. Data are mean ± SEM.  
These results were completely unexpected as they question previous theories 
published in the literature regarding the role of Ide in hepatic insulin clearance. 
In
s
u
li
n
 F
a
s
ti
n
g
 (
n
g
/m
L
)
1  M o n th 3  M o n th s
0 .0
0 .1
0 .2
0 .3
0 .4
0 .5 BA
In
s
u
li
n
 N
o
n
-F
a
s
ti
n
g
 (
n
g
/m
L
)
1  M o n th 3  M o n th s
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
In
s
u
li
n
 N
o
n
-F
a
s
ti
n
g
 (
n
g
/m
L
)
1  M o n th 3  M o n th s
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
W T
L -ID E -K O
In
s
u
li
n
 F
a
s
ti
n
g
 (
n
g
/m
L
)
1  M o n th 3  M o n th s
0 .0
0 .1
0 .2
0 .3
0 .4
In
s
u
li
n
 N
o
n
-F
a
s
ti
n
g
 (
n
g
/m
L
)
1  M o n th 3  M o n th s
0 .0
0 .5
1 .0
1 .5
2 .0BA
In
s
u
li
n
 N
o
n
-F
a
s
ti
n
g
 (
n
g
/m
L
)
1  M o n th 3  M o n th s
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
W T
L -ID E -K O
 89 
 
Calculation of the HOMA index was used as a confirmatory test to demonstrate 
the presence of insulin resistance in the L-IDE-KO mice. As shown in Figure 46, 
1- and 3-month-old L-IDE-KO female mice exhibited insulin resistance since their 
HOMA values are significantly higher than WT mice. 
 
Figure 46: HOMA index in L-IDE-KO and WT female mice. HOMA index in 1- and 3-month-old L-IDE-
KO and WT female mice was calculated as described in the Materials and Methods section. n= 11-23 per 
genotype. Results are represented as mean + SEM. * p < 0.05 vs. WT by Students´ T-test. 
Similarly, 3-month-old L-IDE-KO male mice exhibited insulin resistance 
(Figure 47). However, 1-month-old L-IDE-KO male mice, did not show insulin 
resistance (Figure 47). These data are in good agreement with those presented 
in Figure 42 and 43.  
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Figure 47: HOMA index in L-IDE-KO and WT male mice. HOMA index in 1- and 3-month-old L-IDE-KO 
and WT male mice was calculated as described in the Materials and Methods section. n= 8-15 per genotype. 
Results are represented as mean + SEM. * p < 0.05 vs. WT by Students´ T-test. 
5.2.7 Hepatic Ide ablation does not alter plasma lipid profiles in L-IDE-KO 
mice 
Insulin resistance is closely associated with dyslipemia. Therefore, we next 
investigated the impact of hepatic Ide ablation on plasma triglycerides and 
cholesterol levels. As shown in Figure 48, fasting and non-fasting plasma 
triglyceride levels of 1- and 3-month-old L-IDE-KO female mice remained 
unchanged compared to WT mice. Likewise, no significant differences were 
found in fasting and non-fasting plasma cholesterol levels (Figure 49). 
 
Figure 48: Plasma triglycerides levels in L-IDE-KO and WT female mice. Plasma triglycerides levels 
were assessed as described in the Materials and Methods section. (A) Fasting triglycerides levels in 1 and 
3-month-old L-IDE-KO and WT female mice. n= 11-23 per genotype. (B) Non-fasting triglycerides levels in 
1 and 3-month-old L-IDE-KO and WT female mice. n= 11-23 per genotype. Data are mean ± SEM. 
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Figure 49: Plasma cholesterol levels in L-IDE-KO and WT female mice. Plasma cholesterol levels 
were assessed as described in the Materials and Methods section. (A) Fasting cholesterol levels in 1 and 3-
month-old L-IDE-KO and WT female mice. n= 11-23 per genotype. (B) Non-fasting cholesterol levels in 1 
and 3-month-old L-IDE-KO and WT female mice. n= 11-23 per genotype. Data are mean ± SEM. 
Similarly, fasting and non-fasting plasma triglycerides levels of 1- and 3-month-
old L-IDE-KO male mice remained unchanged compared to WT mice (Figure 
50). Likewise, no significant differences were found in fasting and non-fasting 
plasma cholesterol levels in 1-month-old L-IDE-KO male mice compared to WT 
mice (Figure 51). Surprisingly, fasting and non-fasting plasma cholesterol levels 
in 3-month-old L-IDE-KO male mice were lower than their littermate WT mice. 
 
Figure 50: Plasma triglycerides levels in L-IDE-KO and WT male mice. Plasma triglycerides levels 
were assessed as described in the Materials and Methods section. (A) Fasting triglycerides levels in 1 and 
3-month-old L-IDE-KO and WT male mice. n= 8-15 per genotype. (B) Non-fasting triglycerides levels in 1 
and 3-month-old L-IDE-KO and WT male mice. n= 8-15 per genotype. Data are mean ± SEM. 
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Figure 51: Plasma cholesterol levels in L-IDE-KO and WT male mice. Plasma cholesterol levels were 
assessed as described in the Materials and Methods section. (A) Fasting cholesterol levels in 1 and 3-
month-old L-IDE-KO and WT male mice. n= 8-15 per genotype. (B) Non-fasting cholesterol levels in 1 and 
3-month-old L-IDE-KO and WT male mice. n= 8-15 per genotype. Data are mean ± SEM. * p < 0.05 vs. WT 
by Students´ T-test. 
In summary, despite the finding that L-IDE-KO mice exhibit marked insulin 
resistance, overall plasma lipid profiles remained unchanged. Notably, in a sex- 
and age-dependent manner, L-IDE-KO male mice showed diminished plasma 
cholesterol levels. 
In order to further elucidate the molecular mechanisms by which hepatic 
ablation of Ide is associated with glucose intolerance and insulin resistance, we 
measured plasma glucagon levels in L-IDE-KO and their littermate WT mice. This 
hormone regulates glucose homeostasis under fasting conditions, opposing the 
action of insulin. In addition, glucagon is a substrate of IDE protease activity. 
As shown in Figure 52, fasting and non-fasting plasma glucagon levels of 1- 
and 3-month-old L-IDE-KO female mice remaining unchanged as compared to 
WT mice. It should be noted that non-fasting plasma glucagon levels in 1-month-
old L-IDE-KO female mice exhibited a modest, but statistically non-significant 
elevation (Figure 52.B). 
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Figure 52: Plasma glucagon levels in L-IDE-KO and WT female mice. Plasma glucagon levels were 
assessed as described in the Materials and Methods section. (A) Fasting glucagon levels in 1 and 3-month-
old L-IDE-KO and WT female mice. n= 7-11 per genotype. (B) Non-fasting glucagon levels in 1 and 3-month-
old L-IDE-KO and WT female mice. n= 7-11 per genotype. Data are mean ± SEM.  
Similarly, fasting plasma glucagon levels of 1- and 3-month-old L-IDE-KO male 
mice remained unchanged compared to WT mice (Figure 53). Surprisingly, non-
fasting plasma glucagon levels in 1-month-old L-IDE-KO male mice were higher 
than their littermate WT mice (Figure 53.B). At 3 months of age, some degree of 
elevation persisted, although this did not achieve statistical significance (Figure 
53.B).  
 
Figure 53: Plasma glucagon levels in L-IDE-KO and WT male mice. Plasma glucagon levels were 
assessed as described in the Materials and Methods section. (A) Fasting glucagon levels in 1- and 3-month-
old L-IDE-KO and WT male mice. n= 8-15 per genotype. (B) Non-fasting glucagon levels in 1- and 3-month-
old L-IDE-KO and WT male mice. n= 6-15 per genotype. Data are mean ± SEM. * p < 0.05 vs. WT by 
Students´ T-test. 
In summary, L-IDE-KO mice exhibited augmented plasma glucagon levels, 
potentially due to a reduced capacity for glucagon plasma clearance. This 
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phenotype was more evident in 1-month-old L-IDE-KO male mice, but with aging 
shifted towards a more subtle phenotype. 
IDE is a metalloprotease that, in addition to insulin and glucagon, degrades 
amylin and Aβ40159,160. On the other hand, insulin resistance triggers increased 
secretion of oligomerized amylin from pancreatic islets in the blood185; whereas 
plasma Aβ40 levels are closely associated with insulin resistance186. To 
investigate the impact of hepatic Ide ablation on plasma levels of amylin and 
Aβ40, plasma samples from L-IDE-KO and WT mice were assayed as described 
in the Material and Methods section. As shown in Figure 54, Aβ40 levels were 
significantly reduced in 3-month-old L-IDE-KO female mice, compared to WT 
mice. However, amylin levels remained unchanged (Figure 55). Likewise, 
plasma Aβ40 and amylin levels in 3-month-old L-IDE-KO male mice remained 
unchanged, compared to WT mice (Figure 56 and 57). 
 
Figure 54: Plasma Aβ40 levels in L-IDE-KO and WT female mice. Fasting plasma Aβ40 levels were 
assessed in 3-month-old L-IDE-KO and WT female mice as described in the Materials and Methods section. 
n= 11-12 per genotype. Data are mean ± SEM. * p < 0.05 vs. WT by Students´ T-test. 
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Figure 55: Plasma amylin levels in L-IDE-KO and WT female mice. Fasting plasma amylin levels 
were assessed in 3-month-old L-IDE-KO and WT female mice as described in the Materials and Methods 
section. n= 12-13 per genotype. Data are mean ± SEM.  
 
Figure 56: Plasma Aβ40 levels in L-IDE-KO and WT male mice. Fasting plasma Aβ40 levels were 
assessed in 3-month-old L-IDE-KO and WT male mice as described in the Materials and Methods section. 
n= 10-15 per genotype. Data are mean ± SEM.  
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Figure 57: Plasma amylin levels in L-IDE-KO and WT male mice. Fasting plasma amylin levels were 
assessed in 3-month-old L-IDE-KO and WT male mice as described in the Materials and Methods section. 
n= 10-14 per genotype. Data are mean ± SEM. 
In summary, these results demonstrate that plasma Aβ40 and amylin are not 
associated with glucose intolerance and insulin resistance in L-IDE-KO mice. 
Because IDE is implicated in the degradation of these substrates, such that 
genetic deletion should increase, rather than decrease their levels, these results 
suggest that hepatic IDE does note not participate in the in vivo plasma clearance 
of Aβ40 and amylin. 
It has been proposed that IDE participates in hepatic insulin clearance157,170. 
However, we have shown in this work that plasma insulin levels remained 
unchanged in L-IDE-KO, compared to WT mice. To clarify the role of IDE in 
hepatic insulin clearance in vivo, we performed an insulin clearance test by an 
intra-orbital insulin injection as described in the Material and Methods section. 
Contrary to expectations, insulin clearance in 3-month-old L-IDE-KO female 
and male mice were similar to their littermate WT mice (Figure 58 and 59).  
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Figure 58: Hepatic insulin clearance test of L-IDE-KO and WT female mice. (A) 3-month-old L-IDE-
KO and WT female mice were anesthetized and infected intra-orbitally with human insulin (1 nmol/kg body 
weight). Afterwards, blood was collected at the indicated time points. Plasma human insulin was assessed 
as described in the Materials and Methods section. (B) AUC of hepatic insulin clearance test. n= 8 per 
genotype. Data are mean ± SEM. 
 
Figure 59: Hepatic insulin clearance test of L-IDE-KO and WT male mice. (A) 3-month-old L-IDE-
KO and WT male mice were anesthetized and infected intra-orbitally with human insulin (1 nmol/kg body 
weight). Afterwards, blood was collected at the indicated time points. Plasma human insulin was assessed 
as described in the Materials and Methods section. (B) AUC of hepatic insulin clearance test. n= 6-9 per 
genotype. Data are mean ± SEM. 
Extrahepatic tissues such as kidneys and skeletal muscle are also involved in 
plasma insulin clearance in vivo96.  Therefore, we decided to analyze IDE levels 
in kidneys and skeletal muscle of L-IDE-KO mice, in order to test the hypothesis 
that elevations in IDE in those tissues could counteract the absence of IDE within 
liver to regulate plasma insulin clearance in L-IDE-KO mice.  
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On the one hand, western blot analyses indicated that IDE protein levels in the 
kidney of L-IDE-KO mice were decreased in comparison to WT mice (Figure 60).  
 
Figure 60: IDE levels in kidneys of L-IDE-KO and WT male mice. (A) Representative western blot of 
kidney lysates (40 µg protein/sample) isolated from 3-month-old L-IDE-KO and WT male mice using anti-
IDE and anti-Actin antibodies. (B) Relative amounts of IDE, after normalizing to actin. n= 8 per genotype. 
Data are mean ± SEM. * p < 0.05 vs. WT by Students´ T-test. 
On the other hand, IDE levels in skeletal muscle analyzed by western blot 
remained unchanged in L-IDE-KO compared to WT mice (Figure 61). 
 
Figure 61: IDE levels in the skeletal muscle of L-IDE-KO and WT male mice. (A) Representative 
western blot of skeletal muscle lysates (40 µg protein/sample) isolated from 3-month-old L-IDE-KO and WT 
male mice using anti-IDE and anti-Actin antibodies. (B) Relative amounts of IDE, after normalizing to actin. 
n= 6 per genotype. Data are mean ± SEM. 
In summary, hepatic deletion of Ide does not alter in vivo plasma insulin 
clearance. In addition, extrahepatic IDE levels in tissues such as skeletal muscle 
and kidneys do not compensate for the loss of hepatic IDE, since IDE levels in 
kidneys were slightly reduced and in skeletal muscle remained unchanged.  
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These findings suggest that IDE is not the principal or rate-limiting factor 
involved in hepatic insulin clearance, because insulin clearance is unaltered in 
the absence of hepatic Ide (L-IDE-KO).  
5.2.11 Hepatic Ide ablation impairs hepatic insulin signaling.  
To help elucidate the molecular basis underlying the insulin resistance 
observed in L-IDE-KO mice, we analyzed multiple components of the intracellular 
insulin-signaling pathway in liver and skeletal muscle, two key tissues involved in 
the regulation of whole-body glucose homeostasis.  
To this end, 3-month-old L-IDE-KO and WT male mice were fasted overnight, 
followed by an intraperitoneal injection of a bolus of insulin (0.75 U/Kg) or saline 
solution. Ten minutes later, mice were euthanized and tissues were dissected.  
Hepatic Ide deletion resulted in a significant 30% reduction of IRβ in the 
hepatocytes plasma membrane of L-IDE-KO mice (Figure 62), consistent with 
previous findings in total IDE knockout mice170. Furthermore, insulin-mediated 
activation of the IRβ was impaired by 55% in L-IDE-KO mice compared to WT 
mice (Figure 63).  
 
Figure 62: Plasma membrane IRβ levels in the liver of L-IDE-KO and WT male mice. (A) 
Representative western blot of liver lysates (40 µg protein/sample) isolated from 3-month-old L-IDE-KO and 
WT male mice, using anti-IRβ and anti-Na+/K+ATPase antibodies. (B) Relative amounts of IRβ, after 
normalizing to Na+/K+ATPase. n= 6 per genotype. Data are mean ± SEM. * p < 0.05 vs. WT by ANOVA. 
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Figure 63: Plasma membrane p-IRβ levels in the liver of L-IDE-KO and WT male mice. (A) 
Representative western blots of liver lysates (40 µg protein/sample) isolated from 3-month-old L-IDE-KO 
and WT male mice, using anti-p-IRβ and anti-IRβ antibodies. (B) Relative amounts of p-IRβ, after 
normalizing to IRβ. n= 6 per genotype. Data are mean ± SEM. * p < 0.05 vs. WT by ANOVA. 
AKT1 phosphorylation (Figure 64), which is involved in cell survival, protein 
synthesis and inhibition of apoptosis, and AKT2 phosphorylation (Figure 65), 
which is involved in metabolism exclusively, were both impaired, exhibiting 
significant reductions of 45% and 40%, respectively. Given that AKT1/2 
phosphorylation is downstream of insulin-induced IR autophosphorylation, these 
results are in excellent agreement with those in Figure 63. 
 
Figure 64: p-AKT1(Ser473) levels in the liver of L-IDE-KO and WT male mice. (A) Representative 
western blots of liver lysates (40 µg protein/sample) isolated from 3-month-old L-IDE-KO and WT male mice, 
using anti-p-AKT1(Ser473) and anti-AKT1 antibodies. (B) Relative amounts of p-AKT1(Ser473), after 
normalizing to AKT1. n= 6 per genotype. Data are mean ± SEM. * p < 0.05 vs. WT by ANOVA. 
BA
p
-I
R

 /
 I
R

 (
A
.U
.)
0
5
1 0
1 5
2 0
W T L -ID E  K O
In s u lin - + - +
*
*
n .s .
IRβ
p-IRβ
Insulin - - - + +     + - - - + +     +
WT L-IDE-KO
Na+/K+ATPase
p
-A
K
T
1
(S
e
r
4
7
3
) 
/ 
A
K
T
1
 (
A
.U
.)
0
2
4
6
W T L -ID E  K O
In s u lin - + - +
*
*
*
p-AKT1 (Ser 473)
AKT1
Actin
Insulin - - - + +     + - - - + +     +
WT L-IDE-KO
BA
 101 
 
 
Figure 65: p-AKT2(Ser474) levels in the liver of L-IDE-KO and WT male mice. (A) Representative 
western blots of liver lysates (40 µg protein/sample) isolated from 3-month-old L-IDE-KO and WT male mice, 
using anti-p-AKT2(Ser474) and anti-AKT2 antibodies. (B) Relative amounts of p-AKT2(Ser474), after 
normalizing to AKT2. n= 6 per genotype. Data are mean ± SEM. * p < 0.05 vs. WT by ANOVA. 
We also analyzed GSK3, an enzyme involved in hepatic glycogen synthesis, 
which is downstream of AKT in the insulin-signaling pathway. Upon insulin 
stimulation, AKT phosphorylates and inactivates GSK3, which in turn restores 
GS activity, leading to glycogen synthesis. Unexpectedly, hepatic deficiency of 
Ide was associated with 3.5-fold increase in GSK3 phosphorylation levels in the 
absence of insulin, and 1.5-fold in the presence of insulin compared to WT mice 
(Figure 66). 
 
Figure 66: p-GSK3α levels in the liver of L-IDE-KO and WT male mice. (A) Representative western 
blots of liver lysates (40 µg protein/sample) isolated from 3-month-old L-IDE-KO and WT male mice, using 
anti-p-GSK3α and anti-GSK3 antibodies. (B) Relative amounts of p-GSK3α, after normalizing to GSK3. n= 
6 per genotype. Data are mean ± SEM. * p < 0.05 vs. WT by ANOVA. 
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We hypothesized that the increase of GSK3 phosphorylation levels was due 
to compensatory mechanisms to allow glycogen synthesis, since reduced AKT 
activation led to lower capacity for glycogen synthesis in response to insulin in L-
IDE-KO mice. 
For this reason, we decided to analyze the glycogen levels stored in the liver 
of L-IDE-KO and WT mice in non-fasting conditions. As shown in Figure 67, 
hepatic Ide ablation did not alter glycogen levels in L-IDE-KO mice as compared 
to WT mice. Taken together, these results suggest that Ide deficiency in liver 
does not alter the capacity for storing glycogen in the liver, at least not by a 
mechanism involving phosphorylation of GSK3 independently of AKT. 
 
Figure 67: Hepatic glycogen levels in L-IDE-KO and WT male mice. Non-fasting livers of 3-month-
old L-IDE-KO and WT male mice were used to quantify the amount of glycogen deposits as described in the 
Materials and Methods section. n= 4 per genotype. Data are mean ± SEM. 
On the other hand, analysis of insulin-signaling pathway in skeletal muscle by 
western blots indicated that hepatic Ide ablation did not alter insulin-mediated 
stimulation of the insulin-signaling pathway, as AKT phosphorylation levels 
revealed (Figure 68).  
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Figure 68: p-AKT(Ser473) levels in the skeletal muscle of L-IDE-KO and WT male mice. (A) 
Representative western blots of skeletal muscle lysates (40 µg protein/sample) isolated from 3-month-old L-
IDE-KO and WT male mice, using anti-p-AKT(Ser473) and anti-AKT antibodies. (B) Relative amounts of p-
AKT(Ser473), after normalizing to AKT. n= 6 per genotype. Data are mean ± SEM. * p < 0.05 vs. WT by 
ANOVA. 
Under physiological conditions, one of the actions of insulin on adipose tissue 
is to suppress lipolysis (i.e. the release of FFAs into bloodstream) in the fed state, 
because no extra energy supply is required by the whole organism. 
Hence, we investigated the impact of Ide deficiency on the levels of circulating 
FFAs. To this end, fasted 3-month-old L-IDE-KO and WT male mice were 
intraperitoneally injected with a bolus of human insulin (0.75 U/Kg) or saline 
solution, and 10 min later, mice were euthanized, plasma was collected and FFAs 
levels were assessed as described in the Material and Methods section. 
As expected, insulin reduced FFAs levels in control and L-IDE-KO mice 
compared to saline injections in female (Figure 69) and male (Figure 70) mice. 
Interestingly, insulin lowered by 40% plasma FFAs levels in L-IDE-KO female 
mice (Figure 69) and by 50% in male L-IDE-KO (Figure 70) compared to WT 
mice. 
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Figure 69: Plasma FFAs concentrations in L-IDE-KO and WT female mice in response to insulin. 
Fasted plasma FFAs, from 3-month-old L-IDE-KO and WT female mice, were assessed as described in the 
Materials and Methods section. n= 5-9 per genotype. Data are mean ± SEM. * p < 0.05 vs. WT by ANOVA. 
 
Figure 70: Plasma FFAs concentrations in L-IDE-KO and WT male mice in response to insulin. 
Fasted plasma FFAs, from 3-month-old L-IDE-KO and WT male mice, were assessed as described in the 
Materials and Methods section. n= 4-8 per genotype. Data are mean ± SEM by ANOVA. 
Taken together, these results suggest that hepatic ablation of Ide improves 
insulin sensitivity in the adipose tissue of L-IDE-KO mice.  
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In summary, genetic deletion of Ide in liver significantly alters the intracellular 
insulin-signaling pathway by reducing both the levels and the insulin-
responsiveness of plasma membrane IRβ. Consequently, insulin-mediated 
activation of AKT is impaired. However, despite this deficiency in intracellular 
insulin signaling, the downstream target of AKT, GSK3, is phosphorylated and 
inactivated by an unknown mechanism, leading to a correct regulation of 
glycogen synthesis, as indicated by unaltered stores of hepatic glycogen in L-
IDE-KO mice. Regarding the impact of hepatic insulin resistance on peripheral 
insulin sensitivity, insulin signaling in skeletal muscle was not affected by hepatic 
IDE deficiency but the levels of circulating FFAs suggested improved insulin 
sensitivity in the adipose tissue of L-IDE-KO mice. 
Under physiological conditions during the non-fasting state, insulin inhibits 
hepatic gluconeogenesis. However, under pathophysiological conditions, such 
as insulin resistance, the suppression of hepatic gluconeogenesis can be 
severely attenuated. In this way, hepatic glucose production is uncontrolled, 
leading to hyperglycemia. 
To investigate the effects of hepatic Ide ablation on the regulation of 
gluconeogenesis, we analyzed liver mRNA levels of Pck1 and G6pc using RT-
qPCR as described in Material and Methods section. As shown in Figure 71, 
fasting and non-fasting mRNA levels of Pck1 were elevated by 15% and 70%, 
respectively, in 3-month-old L-IDE-KO male mice as compared to WT mice.  
5.2.12 Hepatic ablation of Ide augments gene expression of Pck1 and G6pc 
in L-IDE-KO mice 
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Figure 71: Fasting and non-fasting relative mRNA levels of Pck1 in L-IDE-KO and WT male mice. 
Livers from 3-month-old L-IDE-KO and WT male mice were collected, RNA isolated, and quantified by RT-
qPCR. All samples were normalized to L18. n= 4 per genotype. Data are mean ± SEM. * p < 0.05 vs. WT 
by Students´ T-test. 
Likewise, fasting and non-fasting mRNA levels of G6pc were elevated by 20% 
and 40%, respectively, in 3-month-old L-IDE-KO male mice as compared to WT 
mice (Figure 72).  
 
Figure 72: Fasting and non-fasting relative mRNA levels of G6pc in L-IDE-KO and WT male mice. 
Livers from 3-month-old L-IDE-KO and WT male mice were collected, RNA isolated, and quantified by RT-
qPCR. All samples were normalized to L18. n= 4 per genotype. Data are mean ± SEM. * p < 0.05 vs. WT 
by Students´ T-test. 
In summary, these data demonstrate that impaired hepatic insulin signaling in 
L-IDE-KO mice leads to an upregulation of gluconeogenic genes in both, fasting 
and non-fasting conditions. In addition, these results begin to explain the 
molecular mechanisms by which Ide deficiency leads to glucose intolerance and 
augmented blood glucose levels in L-IDE-KO mice. 
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To confirm that hepatic insulin resistance developed by L-IDE-KO mice 
induced an increase of hepatic gluconeogenesis process, we performed an 
IPPTT. 
Surprisingly, neither L-IDE-KO female mice (Figure 73) nor L-IDE-KO male 
mice (Figure 74) showed any difference in hepatic gluconeogenesis values 
regarding to WT mice, during the IPPTT. 
 
Figure 73: IPPTT of 3-month-old L-IDE-KO and WT female mice. (A) 3-month-old L-IDE-KO and WT 
female mice were intraperitoneally injected with a bolus of pyruvate at a dose of 2 g/kg of body weight after 
an overnight fasting. Glucose measurements were done at the indicated times. (B) AUC of IPPTT. n= 12-21 
per genotype. Data are mean ± SEM. 
 
Figure 74: IPPTT of 3-month-old L-IDE-KO and WT male mice. (A) 3-month-old L-IDE-KO and WT 
male mice were intraperitoneally injected with a bolus of pyruvate at a dose of 2 g/kg of body weight after 
an overnight fasting. Glucose measurements were done at the indicated times. (B) AUC of IPPTT. n= 12-13 
per genotype. Data are mean ± SEM. 
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These results suggest that pyruvate is not a major gluconeogenic substrate for 
hepatic gluconeogenesis in our experimental conditions. However, it is plausible 
to propose that administration of other gluconeogenic substrates such as 
glycerol, amino-acids or lactate, may result in enhanced hepatic glucose 
production. 
With the purpose of investigating whether insulin action alters IDE protein 
levels, we analyzed the IDE content in liver and skeletal muscle by western blots 
in L-IDE-KO and WT mice. 
Surprisingly, insulin treated WT mice showed lower hepatic IDE protein levels 
than mice injected with saline solution (Figure 75). 
 
Figure 75: IDE levels in the liver of L-IDE-KO and WT male mice. (A) Representative western blots 
of liver lysates (40 µg protein/sample) isolated from 3-month-old L-IDE-KO and WT male mice using anti-
IDE and anti-actin antibodies. (B) Relative amounts of IDE, after normalizing to actin. n= 6 per genotype. 
Data are mean ± SEM. *p < 0.05 vs. WT by Students´ T-test. 
In contrast, insulin did not alter the protein levels of IDE in skeletal muscle of 
L-IDE-KO and WT mice (Figure 76).  
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Figure 76: IDE levels in the skeletal muscle of L-IDE-KO and WT male mice. (A) Representative 
western blots of skeletal muscle lysates (40 µg protein/sample) isolated from 3-month-old L-IDE-KO and WT 
male mice using anti-IDE and anti-Actin antibodies. (B) Relative amounts of IDE, after normalizing to Actin. 
n= 6 per genotype. Data are mean ± SEM.  
These results uncover an unidentified post-transcriptional regulatory 
mechanism of IDE in the liver. 
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A hallmark of obesity and T2DM is the presence of insulin resistance. Despite 
many efforts to elucidate the etiology of insulin resistance, the precise 
mechanism(s) responsible remain undetermined. Taking into account the 
epidemic of obesity20–22, and the fact that most obese patients are insulin 
resistant23,24, the principal hypotheses put forward to explain this condition have 
emerged from an adipocentric point of view. On the one hand, fat overload theory 
postulates that ectopic deposition of elevated circulating plasma FFAs in 
peripheral tissues led to accumulation of toxic lipid intermediaries, such as 
diacylglycerol, which causes inhibition of the intracellular insulin-signaling 
pathway by activation of protein kinase C (PKC) isoforms70,77. On the other hand, 
inflammation theory postulates that circulating pro-inflammatory cytokines, 
stemming from dysfunctional adipose tissue, are involved in the interruption of 
intracellular insulin-signaling pathway through a cross-talk with inflammatory 
signaling pathways, such as inhibitor of nuclear factor kappa-B / nuclear factor 
kappa-light-chain-enhancer of activated B cells (IKKβ/NF-κB) pathway187. 
However, the traditional paradigm is confounded by the existence of 
metabolically obese normal weight (MONW) patients, around 10-27% of lean 
individuals (BMI< 25) exhibit insulin resistance188,189; and by the metabolically 
healthy obese (MHO) subjects, around 13-29% of obese patients do not present 
insulin resistance188–190. For both scenarios, current hypotheses fail to explain 
insulin resistance etiology.  
Delineating the precise etiology (or etiologies) of insulin resistance will not be 
trivial, but it would represent a critical step towards the development of novel 
drugs for the prevention, treatment and cure of metabolic alterations, such as 
impaired glucose homeostasis. Given the contradictions in the literature, it is 
necessary to revise our current hypotheses, in order to find new therapeutic 
targets for the treatment of T2DM. 
6 DISCUSSION 
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Current treatments of T2DM primarily focus on two actions: to improve insulin 
secretion by secretagogues; and to improve peripheral insulin sensitivity. In fact, 
current treatments usually combine both types, secretagogues as sulfonylureas 
(SFUs) or glinides, together with drugs that increase insulin effects as 
pioglitazone or metformin191,192. On the other hand, incretins are also commonly 
used to stimulate insulin secretion by pancreatic β-cells and to reduce blood 
glucose levels, such as dipeptidyl peptidase-4 (DPP-4) inhibitors or glucagon-like 
peptide-1 (GLP-1) agonist193.  
Deciphering the role of IDE as a new therapeutic target for the treatment of 
T2DM 
Recently, it has been proposed that pharmacological approaches towards 
regulation of hepatic insulin homeostasis may help diabetic patients to achieve 
better metabolic control of whole-body glucose homeostasis173. But these 
approaches suffer from a lack of knowledge about the regulation of hepatic insulin 
clearance. Several studies describe IDE as the major enzyme involved in the 
insulin degradation process in vitro165. So far, emerging knowledge using the 
total-IDE-KO mouse has spurred the notion that inhibition of IDE activity leads to 
hyperinsulinemia170. However, this mouse model developed insulin resistance 
and glucose intolerance, which was explained by the authors as a secondary 
phenotype due to hyperinsulinemia170. These observations have prompted the 
development of new compounds with inhibitory activity on IDE, but with 
controversial results regarding the capacity of regulation of whole-body glucose 
homeostasis173. Therefore, the role of IDE in the regulation of hepatic plasma 
insulin clearance, and the effectiveness of pharmacological approaches to inhibit 
IDE activity remains unclear. 
To shed light to these issues, we have developed a novel mouse model 
featuring liver-specific knockout of IDE (L-IDE-KO). We demonstrate in this work 
that ablation of hepatic Ide causes hyperglycemia, glucose intolerance and 
insulin resistance, independently of plasma insulin levels, food intake and body 
weight in male and female mice of 1 and 3 months of age. In L-IDE-KO female 
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mice, this phenotype is developed at early ages, but in L-IDE-KO male mice, the 
phenotype gets worse with aging. Insulin resistance, in both female and male L-
IDE-KO mice, was assessed by different experimental approaches such as IPITT 
and HOMA index.  
In this way, our results partially coincide with those obtained during the 
metabolic characterization of total-IDE-KO mice, where Farris et al.157 and Abdul-
Hay et al.170 found that IDE total knock-out mice had increased fasting circulating 
insulin levels, were glucose intolerant and showed insulin resistance; however, 
Steneberg et al.171 found that total-IDE-KO mice had normal fasting circulating 
insulin concentrations and did not find insulin resistance, despite being 
hyperglycemic and glucose intolerant.  
In our study, to elucidate IDE's role in hepatic insulin clearance, plasma insulin 
levels were measured after intra-orbital insulin dose-administration, with the 
purpose of assessing the liver’s ability to carry out insulin clearance processes in 
the presence or absence of IDE. Our data showed no differences in hepatic 
insulin clearance ratio between WT and L-IDE-KO mice. In addition, we must take 
into account that clearance of circulating insulin occurs primarily in liver and in 
less amount in the kidney. In this way, in order to reject the hypothesis about a 
possible insulin clearance compensation by the kidney as a response of hepatic 
IDE absence, kidney IDE amount was analyzed in WT and L-IDE-KO mice. The 
observed results not only showed that there is no IDE overexpression as 
compensatory mechanism in the kidney, but actually showed a decrease of 
kidney IDE levels. Therefore, these findings indicate that IDE is not the principal 
or rate-limiting factor involved in insulin clearance processes in vivo, supporting 
the theory raised by Durham et al.175, but they also help to clarify the mechanisms 
underlying hepatic insulin clearance. In addition, in view of our results, we can 
hypothesize that the phenotypes exhibited by total-IDE-KO mice characterized 
by Farris et al.157 and Abdul-Hay et al.170, which include hyperinsulinemia, 
glucose intolerance and insulin resistance, are a consequence of the insulin 
resistance generated mainly in peripheral tissues, and not because of a 
deficiency in insulin clearance associated with the lack of IDE. Furthermore, one 
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needs to take into account that their mice are total KO with IDE lost in all cell 
types, which complicates the interpretation of the observed phenotype. 
By utilizing Cre-mediated, tissue-specific ablation of Ide, we have developed 
an ideal mouse model to help elucidate the involvement of IDE in hepatic insulin 
clearance. By excluding IDE as a significant mediator of this process, we can 
postulate that other proteins might be more critical for insulin clearance, such as 
carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), a 
substrate of the IR in liver which has been described as the main modulator of 
hepatic insulin clearance by Poy et al.98. 
In summary, although some studies using the total-IDE-KO mouse model 
support the notion that hyperinsulinemia is induced by a deficiency in hepatic 
plasma insulin clearance associated with the deficiency of IDE; our L-IDE-KO 
mouse model does not support the notion that IDE has a major role in hepatic 
plasma insulin clearance. 
Hepatic depletion of IDE impairs intracellular insulin signaling 
The hyperglycemia, glucose intolerance and insulin resistance displayed by L-
IDE-KO mice were associated with reduced levels of membrane-associated IRβ. 
Abdul-Hay et al.170 showed similar results, albeit in the context of 
hyperinsulinemia which was not present in our mouse model. In addition, our 
study associates the lack of hepatic IDE, not only with a decrease of IR, but also 
with a reduction of insulin receptor phosphorylation levels in the presence of 
insulin. This is probably due to a failure in insulin receptor recycling process once 
it is endocytosed, as a result of this failure it will be an inability to dissociate 
insulin-IR complexes, remaining the insulin-IR complex into endosomes in the 
cytosol. As consequence, hepatic insulin-signaling pathway is blocked in 
absence of hepatic IDE.  
Given that insulin regulates a plethora of metabolic processes in the liver, such 
as protein and lipid synthesis, cellular proliferation and differentiation, and 
glucose metabolism, we were interested to analyze the intracellular insulin-
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signaling pathway in the L-IDE-KO mice. Specifically, we analyzed 
phosphorylation levels of AKT1, involved in protein synthesis, cell survival, and 
inhibition of apoptosis57,194,195; and AKT2, which regulates metabolic processes 
exclusively57,58,194,195. In addition, we must take into account that AKT is 
considered a critical node of the insulin-signaling pathway47 and regulates the 
activity of other kinases downstream, such as: GSK3, involved in glycogen 
production47,59; SREBP-1c, a lipogenesis and cholesterol homeostasis 
regulator60,61; and FoxO1, a gluconeogenesis regulator62,95. Answering this 
concern, we have found that reduced insulin receptor phosphorylation levels 
were associated with impaired insulin signaling at the level of AKT1 and AKT2.  
Consistent with a reduction in the activity of AKT2, we observed that the mRNA 
levels of genes involved in the regulation of gluconeogenesis, such as 
Pck199,134,135 and G6pc137,138, were significantly elevated in the L-IDE-KO mice 
under fasting and non-fasting conditions. We hypothesize that the reduced ability 
of AKT2 to phosphorylate FoxO1 leads to the translocation from the cytoplasm 
to the nucleus of the transcription factor95,97,99. In the nucleus, FoxO1 promotes 
the transcription of Pck1 and G6pc, unleashing hepatic gluconeogenesis. 
Interestingly, the IPPTT did not support this hypothesis, since plasma glucose 
levels remained unaltered during the test. These results may be explained in two 
ways: First, pyruvate is not the best gluconeogenic substrate in our conditions, 
and the test should be repeated using other gluconeogenic substrates such as 
glycerol, lactate, etc. Second, FoxO1 not only controls the expression of 
gluconeogenic genes, but also regulates glycogenolysis. Thus, the main impact 
of insulin resistance on FoxO1 may impact the regulation of glycogenolysis.  
Another downstream target of AKT2 is GSK3, which regulates glycogen 
synthesis. In response to insulin, AKT2 phosphorylates and inactivates GSK3, 
leading to activation of GS and glycogen synthesis. In the absence of insulin, 
AKT2 no longer phosphorylates GSK3, which in turn inactivates GS by 
phosphorylation, leading to inhibition of glycogen synthesis47,59,99. Surprisingly, 
we found that phosphorylation levels of GSK3 were significantly augmented in 
both, fasting and non-fasting conditions, in the L-IDE-KO mice. This result was 
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completely unexpected. We hypothesize that, through an unknown kinase, GSK3 
is phosphorylated in an attempt to compensate for the loss-of-function of AKT2 
and maintain the GS capacity upon insulin stimulation. This compensatory 
mechanism may be responsible for the weak phenotype of blood glucose levels 
in the L-IDE-KO mice.  In addition, this compensatory mechanism may also 
explain that hepatic glycogen levels are similar between L-IDE-KO and control 
littermates. 
On the other hand, regulation of hepatic glycogen stores is also mediated by 
the expression or activity of enzymes involved in the glycogenolysis process, 
such as the glycogen phosphorylase119,127. We have not assessed the activity 
and protein levels of this enzyme in this work, but certainly, we ought to 
investigate the impact of hepatic Ide ablation on glycogenolysis to explain the 
metabolic phenotype of L-IDE-KO mice.  
Likewise, we did not investigate the impact of hepatic IDE ablation on other 
cell processes, such as protein synthesis and apoptosis, which could be studied 
in the future to further clarify the role of IDE in these processes.  
Regulation of IDE levels by insulin in hepatocytes 
Other interesting findings were discovered after liver and skeletal muscle 
analysis of WT mice. For example, the finding that hepatic IDE levels diminished 
under insulin stimulus, while IDE levels in skeletal muscle remained unaltered. In 
fact, Pivovarova et al156 observed increased IDE activity under normal glucose 
concentrations when human hepatoma (HepG2) cells were treated with insulin; 
however, under high glucose concentrations, insulin did not induce changes in 
IDE activity. In this way, these findings suggest that hyperglycemia stablished in 
T2DM induces a disturbance in IDE activity156.  
These data open another research direction, which suggests that IDE function 
is regulated differently depending on the tissue; in addition, IDE probably has 
other functions which have not yet been elucidated.  
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Impact of hepatic depletion of IDE on lipid metabolism 
The liver is a main organ involved in the regulation of glucose and lipid 
metabolism through the action of insulin and glucagon. In the fasting state, the 
predominant hormone is glucagon, which promotes hepatic glycogenolysis and 
gluconeogenesis. In the fed state, insulin takes control of glucose metabolism 
and inhibits glycogenolysis and gluconeogenesis processes. However, insulin 
also regulates hepatic lipid metabolism promoting lipogenesis and fat 
accumulation. Insulin stimulates de novo lipogenesis through the stimulation and 
combined action of three transcription factors: LXR, SREBP-1c and 
carbohydrate-responsive element-binding protein (ChREBP). These transcription 
factors promote the expression of lipogenic genes and fatty acid accumulation in 
the liver. The process involves three steps: 1) de novo lipogenesis, 2) fatty acid 
esterification, and 3) very-low-density lipoprotein (VLDL) secretion196. Because 
insulin is necessary for hepatic lipogenesis, we might hypothesize that hepatic 
insulin resistance would decrease hepatic triglyceride synthesis and secretion, 
leading to reduced plasma triglyceride levels. However, insulin resistance in mice 
and humans is associated with hypertriglyceridemia. How can these two 
observations be reconciled? To resolve this paradox, it has been proposed that 
there may be pathway-selective insulin resistance197,198. That is, there might be 
distinct insulin-sensitive signaling pathways that independently modulate glucose 
and lipid metabolism. The main framework of this concept of selective hepatic 
insulin resistance is grounded in the notion that with selective insulin resistance, 
insulin fails to suppress hepatic glucose output (glycogenolysis and 
gluconeogenesis), and yet still augments hepatic lipogenesis. Overall, this model 
proposes that insulin-mediated regulation of glucose metabolism is impaired, 
whereas insulin-mediated regulation of lipid metabolism remains intact. 
Because our L-IDE-KO mouse model does not exhibit hypertriglyceridemia, 
but hepatic glucose metabolism is altered, we propose that hepatic ablation of 
Ide causes selective hepatic insulin resistance (Figure 77). 
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Figure 77: Selective insulin resistance in the liver of L-IDE-KO mice. Adapted from Brown MS. and Goldstein 
JL.197. 
The liver has the capacity to convert glucose to lipids through de novo 
lipogenesis, but this metabolic feature in physiological terms is a relatively minor 
metabolic pathway. However, under conditions of carbohydrate overfeeding this 
pathway becomes relevant. It would be worthy to investigate the impact of hepatic 
ablation of Ide in mice fed a carbohydrate rich diet. In this line of thinking, 
glycogen synthesis is the metabolic pathway responsible for the major fate of 
glucose in the liver. Spillover of glucose due to impaired glycogen synthesis is 
diverted to glucose oxidation and lipid synthesis. In our mouse model, the 
pathway of glycogen synthesis seems not to be affected by deletion of Ide, which 
may support the hypothesis that glucose partitioning to de novo lipogenesis is not 
affected. 
We propose that hepatic Ide ablation causes selective hepatic insulin 
resistance, i.e. triglycerides synthesis was not affected, cholesterol synthesis 
seems to be altered. In this way, we hypothesize that the regulation of the main 
transcription factors involved in cholesterol synthesis, SREBP-1a and SREBP-
2199, may be downregulated in parallel with hepatic insulin resistance. In this 
manner, the lower circulating cholesterol levels exhibited by L-IDE-KO mice could 
be a result of another selective hepatic insulin resistance which alters the 
expression of SREBP-1a and SREBP-2 transcription factors199 (Figure 78). 
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Figure 78: Liver transcriptional control of cholesterol and triglycerides synthesis. 
Impact of hepatic insulin resistance on peripheral insulin sensitivity 
Hepatic insulin resistance in the L-IDE-KO mouse was not associated with 
skeletal muscle insulin resistance. Insulin was able to stimulate the insulin-
signaling pathway in the muscle cells of L-IDE-KO mice. So far, our knowledge 
about the etiology of muscle insulin resistance is focused on the ectopic 
accumulation of fat in the skeletal muscle68. As reviewed by Samuel and 
Shulman68, intracellular accumulation of diacylglycerol mediates activation of 
protein kinase C-theta (PKCθ) leading to phosphorylation of IRS1/2 in serine 
residues. This molecular mechanism causes impaired insulin signaling and 
diminished translocation of vesicle-containing GLUT4 to plasma membrane. 
Plasma FFA and triglyceride levels are not elevated in our L-IDE-KO mice; this is 
consistent with insulin sensitivity of the skeletal muscle. Therefore, the increase 
in plasma glucose levels in the L-IDE-KO mice most likely is due to impaired 
hepatic glucose metabolism, rather than altered glucose uptake in skeletal 
muscle. 
Likewise, we have observed that insulin-stimulated reductions in plasma FFA 
levels are significantly larger in the L-IDE-KO mice compared to control mice. 
These data support the notion that lipolysis is more effectively suppressable in 
the adipose tissue of the L-IDE-KO mice, which may be due to enhanced insulin 
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sensitivity in this tissue. Further research is warranted to investigate the impact 
of hepatic ablation of Ide on adipose tissue in L-IDE-KO mice. 
Impact of hepatic ablation of Ide on other targets 
IDE has been described as a 110-kDa metalloprotease. The main catalytic 
function attributed to IDE is the degradation of insulin, although it also degrades 
a number of other substrates, including glucagon, amylin and Aß96,159,160. 
It should be noted that IDE has been described as one the main enzymes 
involved in insulin clearance due to its affinity for insulin173,200. However, Durham 
et al.175 proposed that  IDE is not the main enzyme involved in plasma insulin 
clearance in vivo, but they emphasized its fundamental role in amylin clearance. 
We showed that hepatic depletion of Ide is associated with augmented plasma 
glucagon levels. This phenotype was more pronounced at young ages. 
Interestingly, dysregulated glucagon clearance is not accompanied by plasma 
insulin levels alterations at early ages. We must take into account that the plasma 
glucagon clearance is not fully understood. Dobbins et al.201, indicate that 
glucagon clearance in dogs occurs in the liver and kidneys, preferentially in the 
liver201. Other studies propose that glucagon degradation occurs in the plasma 
membrane of hepatocytes through receptors involving both saturable and non-
saturable mechanisms120. However, studies performed by Deacon et al.202, Zhou 
et al.203 and Lefebvre et al.204 in pigs and dogs indicate that kidneys are the most 
important tissue for glucagon elimination, by a molecular mechanism that 
involves the dipeptidyl peptidase-4 (DPP-4) enzyme located in the renal tubular 
brush border. In fact, the mechanism of glucagon clearance process in mice is 
unknown. Therefore, our L-IDE-KO mouse model represents a valuable tool for 
investigating the molecular mechanisms of plasma glucagon clearance. 
On the other hand, IDE is one of the principal known amylin- and Aβ-degrading 
enzymes159,160. First of all, we must keep in mind that amylin and Aβ share 
several features, such as similar β-sheet secondary structures205, bind to the 
same amylin receptor206 and can be degraded by IDE151,160,178. In spite of this, 
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rodent amylin structure is quite different than others, including human amylin, 
because rodent amylin displays proline at residues 20-29 and does not generate 
amyloid fibrils; while, amylin from other species, such as human amylin, create 
β-pleated sheet formation around residues 20-29 of the primary sequence 
generating amyloid fibrils spontaneously207. Amylin is co-secreted with insulin by 
pancreatic β-cells in a ratio of approximately 1:100, and contributes to glycemic 
control208. In addition, increased circulating amylin levels are associated with 
insulin resistance, in which insulin secretion and consequently, amylin secretion 
is augmented. This metabolic alteration induces pancreatic β-cells dysfunction, 
characterized by the accumulation of amyloid deposits209,210. In this context, given 
that amylin and insulin are co-secreted, our findings in L-IDE-KO mice—which 
showed hyperglycemia, glucose intolerance and insulin resistance, but 
unchanged circulating plasma amylin levels—suggest that insulin resistance was 
primarily caused by impaired hepatic insulin signaling, and was not accompanied 
by augmented insulin secretion.  
Summarizing, our analysis and metabolic characterization of L-IDE-KO mice 
resolve conflicting ideas about the role of hepatic IDE in glucose homeostasis 
and insulin action in vivo. The absence of hepatic IDE causes insulin resistance, 
glucose intolerance, and hyperglycemia, through molecular mechanisms which 
involve impaired hepatic insulin signaling, leading to upregulation of 
gluconeogenic genes. In addition, our study supports the notion that IDE has not 
a principal or rate-limiting regulator of plasma insulin levels in vivo, but may be 
more relevant for the hepatic clearance of plasma glucagon. From a therapeutic 
perspective, our results suggest that pharmacological inhibition of IDE would be 
contraindicated as a therapeutic approach to diabetes treatment. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions
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1. We demonstrate that IDE is not the principal enzyme involved in hepatic 
plasma insulin clearance in mice. However, our study reveals a potential 
role of IDE in hepatic plasma clearance of glucagon. 
 
2. The absence of hepatic IDE disrupts whole-body glucose homeostasis 
while triggering insulin resistance in mice. These results suggest that IDE 
is a new agent in the etiology of hepatic insulin resistance. 
 
3. We have identified a new molecular mechanism by which IDE causes 
hepatic insulin resistance independently of the proteolytic activity of IDE. 
This mechanism involves diminished plasma membrane insulin receptor 
levels. 
 
4. Our work challenges the notion that pharmacological inhibition of IDE 
represents a new therapeutic approach for the treatment of T2DM. 
 
7 CONCLUSIONS 
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